Kvartalsrapport Q3 2023

Automatiskt nyckeltalsindex

Detta är sökträffar och textkontext, inte verifierade eller normaliserade redovisningsvärden.

Fulltext

===== SIDA 1 =====

1 
AstraZeneca 
9 November 2023 
9M and Q3 2023 results 
 
Strong momentum in the year to date leads to increased guidance for Total Revenue ex COVID-19 medicines 
and Core EPS  
 
Revenue and EPS summary  
 
   9M 2023   Q3 2023  
   % Change  % Change 
  $m   Actual   CER 1 $m   Actual   CER   
- Product Sales  32,466  1  4  11,018  4  5  
- Alliance Revenue 2   1,004  99  99  377  76  75  
- Collaboration Revenue  317  (28)  (28)  97  (46)  (47)  
Total Revenue  33,787  2  5  11,492  5  6  
Total Revenue ex COVID-19   33,453  12  15  11,492  12  13  
Reported 3 EPS 4  $3.22  >2x  >2x  $0.89  (16)  (6)  
Core 5 EPS  $5.80  10  17  $1.73  4  9  
 
Financial performance (9M 2023 figures unless otherwise stated, growth numbers at CER)  
 
‒ Total Revenue $33,787m, up 5% despite a decline of  $2,896m from COVID-19 medicines 6 
 
‒ Excluding COVID-19 medicines,  both Total Revenue and Product Sales increased 15%  
 
‒ Total Revenue from Oncology medicines increased 20 %, CVRM 7 19%, R&I 8 9%, and Rare Disease 12% 
 
‒ Core Product Sales Gross Margin 9 of 82%, up two percentage points, reflecting the decline in sales of lower 
margin COVID-19 medicines 
 
‒ Core Operating Margin of 35% increased by three pe rcentage points including the previously-announced 
gain from an update to the contractual relationship s for Beyfortus , totalling $712m and recorded in Core 
Other operating income 
  
‒ Core EPS increased 17% to $5.80 
 
‒ FY 2023 Total Revenue excluding COVID-19 medicines  now expected to increase by a low-teens 
percentage at CER 
 
‒ FY 2023 Core EPS now expected to increase by a low  double-digit to low-teens percentage at CER 
 
Pascal Soriot, Chief Executive Officer, AstraZeneca, said:  
  
"Our company continued its strong growth trajectory  in the third quarter with Total Revenue from our 
non ‑COVID-19 medicines up 13% compared to last year. 
  
 
1  Constant exchange rates. The differences between Actual Change and CER Change are due to foreign exchange movements between 
periods in 2023 vs. 2022. CER financial measures are not accounted for according to generally accepted accounting principles (GAAP) 
because they remove the effects of currency movements from Reported results. 
2  Effective 1 January 2023, the Group has updated t he presentation of Total Revenue. For further detai ls of the presentation of Alliance 
Revenue and Collaboration Revenue, see the Basis of  preparation and accounting policies section of the Notes to the Interim financial 
statements section.  
3  Reported financial measures are the financial results presented in accordance with UK-adopted International Accounting Standards and 
International Financial Reporting Standards (IFRSs) as issued by the International Accounting Standards Board (IASB) and International 
Accounting Standards as adopted by the European Union. 
4  Earnings per share. 
5  Core financial measures are adjusted to exclude certain items. The differences between Reported and Core measures are primarily due 
to costs relating to the acquisition of Alexion, amortisation of intangibles, impairments, legal settlements and restructuring charges. A full 
reconciliation between Reported EPS and Core EPS is  provided in Table 13 and Table 14 in the Financial  performance section of this 
document. 
6  The COVID-19 medicines are Vaxzevria , Evusheld , and AZD3152 – the COVID-19 antibody currently in development. 
7  Cardiovascular, Renal and Metabolism. 
8  Respiratory & Immunology. 
9  The calculation of Reported and Core Product Sale s Gross Margin (formerly termed as Gross Margin) ex cludes the impact of Alliance 
Revenue and Collaboration Revenue.

===== SIDA 2 =====

2 
We initiated several Phase III trials of high-poten tial molecules this quarter, including for volrusto mig, our 
PD-1/CTLA-410  bispecific antibody. Our portfolio of bispecifics has the potential to replace the first-generation 
checkpoint inhibitors across a range of cancers. We also initiated a fixed dose combination study of zibotentan 
with Farxiga which has the potential to significantly improve outcomes for patients with kidney disease not well 
controlled on current standard of care.  
  
I am excited about the acceleration of our cardiometabolic and obesity pipeline with today’s licensing agreement 
for ECC5004, a potential best-in-class, oral GLP-1R A 11 . This molecule could offer an important advance, a s 
both a monotherapy and in combinations, for the est imated one billion people living with cardiometabol ic 
diseases such as type-2 diabetes and obesity. 
  
Given the momentum in the year to date we have increased our full-year guidance for Total Revenue excluding 
COVID medicines as well as for Core EPS."  
 
Key milestones achieved since the prior results announcement 
 
‒ Key positive read-outs: datopotamab deruxtecan in metastatic HR 12 -positive breast cancer 
(TROPION-Breast01); Imfinzi in liver cancer (EMERALD-1); Fasenra in EGPA 13  (MANDARA)  
 
‒ Key regulatory approvals: EU approval for Enhertu in HER2 14 -mutant lung cancer (DESTINY-Lung02); China 
approvals for Forxiga in heart failure regardless of ejection fraction (D ELIVER); Calquence  in r/rCLL 15  
(ASCEND); Soliris  in NMOSD 16 . Japan approvals for Lynparza in prostate cancer (PROpel); Enhertu in 
HER2-mutant lung cancer (DESTINY-Lung02) 
 
‒ Other milestones: Tagrisso  granted US Breakthrough Therapy Designation and US  Priority Review in 
combination with chemotherapy for treatment of pati ents with locally advanced or metastatic EGFR m17  
NSCLC 18  (FLAURA2); Enhertu granted US Breakthrough Therapy Designations in HER2-positive colorectal  
cancer (DESTINY-CRC01, DESTINY-CRC02) and multiple types of HER2-expressing tumours 
(DESTINY-PanTumor02) 
 
 
Guidance 
 
The Company updates its Total Revenue and Core EPS guidance for FY 2023 at CER, based on the average 
foreign exchange rates through 2022.  
 
   
Total Revenue is expected to increase by a mid single-digit percentage 
(previously low-to-mid single-digit).  
Excluding COVID-19 medicines, Total Revenue is expected to increase by a low-teens percentage 
(previously low double-digit) . 
Core EPS is expected to increase by a low double-digit to low-teens percentage  
(previously high single-digit to low double-digit) . 
 
 
Other elements of the Income Statement are expected  to be broadly in line with the indications issued in the 
Company's H1 2023 results announcement. 
 
The Company is unable to provide guidance on a Repo rted basis because it cannot reliably forecast mate rial 
elements of the Reported results, including any fai r value adjustments arising on acquisition-related liabilities, 
intangible asset impairment charges and legal settlement provisions. Please refer to the cautionary statements 
section regarding forward-looking statements at the end of this announcement. 
 
10   Programmed cell death protein 1/cytotoxic T-lymphocyte-associated protein 4. 
11   Glucagon-like peptide 1 receptor agonist. 
12   Hormone receptor. 
13   Eosinophilic granulomatosis with polyangiitis. 
14   Human epidermal growth factor receptor 2. 
15   Relapsed or refractory chronic lymphocytic leukaemia. 
16   Neuromyelitis optica spectrum disorder. 
17   Epidermal growth factor receptor mutation. 
18   Non-small cell lung cancer.

===== SIDA 3 =====

3 
 
Currency impact 
 
If foreign exchange rates for October to December 2023 were to remain at the average rates seen in September 
2023, it is anticipated that FY 2023 Total Revenue would incur a low single-digit adverse impact versu s the 
performance at CER, and Core EPS would incur a mid single-digit adverse impact (previously a low-to-mi d 
single-digit adverse impact). 
 
The Company's foreign exchange rate sensitivity analysis is provided in Table 19. 
 
Table 1: Key elements of Total Revenue performance in Q3 2023 
 
  % Change    
 
Revenue type   $m  Actual  CER    
Product Sales   11,018  4  5   ∗ Double-digit growth at CER in Oncology, CVRM  
and Rare Disease 
Alliance Revenue  377  76  75   ∗ $266m for Enhertu  (Q3 2022: $160m) 
∗ $74m for Tezspire  (Q3 2022: $26m) 
Collaboration Revenue   97  (46)  (47)   ∗ $71m for Beyfortus regulatory milestone 
Total Revenue   11,492  5  6   ∗ Excluding COVID-19 medicines , Q3 2023 Total 
Revenue increased by 12% (13% at CER) 
Therapy areas  
 
$m  Actual % CER % 
  
Oncology  
 
4,664  15  17   ∗ Strong performance across key medicines and 
regions  
∗ No milestones from Lynparza in the quarter (Q3 
2022: $75m) 
CVRM   
 
2,687  14  16   ∗ Farxiga up 41% , Lokelma  up 30% (31% at 
CER), roxadustat up 31% (39% CER), Brilinta 
declined 2% (1% at CER)  
R&I  
 
1,549  3  5   ∗ Fasenra up 10%, Breztri  up 66% (69% CER). 
Saphnelo and Tezspire also  continue to grow 
rapidly during their launch phase, partially offset 
by a 12% decline (10% at CER) in Symbicort 
following entry of a generic  competitor in the US 
during the quarter 
V&I 19   
 
312  (64)  (65)   ∗ $nil revenue from COVID-19 mAbs and 
Vaxzevria in the quarter (Q3 2022: $536m and 
$180m respectively) 
∗ Beyfortus $138m, including $50m of Product 
Sales from product supplied to Sanofi, $71m of 
Collaboration Revenue for a regulatory 
milestone and $17m of Alliance Revenue for 
AstraZeneca's share of gross profit outside US 
Rare Disease 
  
 
1,974  13  14   ∗ Ultomiris  up 50% (49% at CER), partially offset 
by decline in Soliris of 13% (12% at CER) 
∗ Strensiq  up 20% (21% at CER) and Koselugo 
up  81% reflecting strong patient demand 
Other Medicines   306  (36)  (32)   ∗ Nexium generic competition in Japan 
Total Revenue   11,492  5  6    
Regions inc.  COVID-19    $m  Actual % CER % 
  
US   4,859  5  4    
Emerging Markets   2,964  4  12    
- China   1,452  (6)  1    
- Ex-China Emerging Markets   1,513  15  25    
Europe   2,392  16  9    
Established RoW   1,276  (10)  (6)    
 
19   Vaccines & Immune Therapies.

===== SIDA 4 =====

4 
Total Revenue inc . COVID-19    11,492  5  6   • Growth rates impacted by lower sales of 
COVID-19 medicines (see table below) 
Regions ex . COVID-19   $m  Actual % CER % 
  
  
US   4,859  12  12    
Emerging Markets   2,964  8  16    
- China   1,452  (6)  1    
- Ex-China Emerging Markets   1,513  25  36    
Europe   2,392  23  16    
Established RoW   1,276  5  10    
Total Revenue ex. COVID-19  11,492  12  13    
 
Table 2: Key elements of financial performance in Q3 2023 
 
 
Metric  
 
Reported  Reported 
change 
Core  Core  
change 
 Comments 20   
Total 
Revenue $11,492m 
 5% Actual      
6% CER $11,492m  5% Actual      
6% CER  
 ∗ Excluding COVID-19  medicines, Q3 2023 
Total Revenue increased by 12% (13% at 
CER) 
∗ See Table 1 and the Total Revenue section 
of this document for further details 
Product 
Sales Gross 
Margin  
81% 
+9pp Actual      
+10pp CER 81% +1pp Actual      
+1pp CER  
 + Favourable mix of sales from Oncology and 
Rare Disease medicines 
+ No sales of COVID-19 medicines 
‒ Increasing mix of products with profit-
sharing 
arrangements, where AstraZeneca books 
Product Sales and records an expense in 
COGS 
21  for the profit share due to its partner  
∗ Variations in Product Sales Gross Margin 
can be expected between periods due to 
product seasonality, foreign exchange 
fluctuations and other effects 
R&D 
expense  $2,584m 
5% Actual      
4% CER $2,485m 5% Actual      
5% CER  
 + Increased investment in the pipeline 
∗ Core R&D-to-Total Revenue ratio of 22%  
(Q3 2022: 21%)  
∗ Year-on- year comparisons can be impacted 
by differences in cost phasing driven by 
study starts and execution  
SG&A 
expense  $4,800m 
12% Actual      
12% CER $3,355m 6% Actual      
7% CER  
 + Market development for recent launches and 
pre-launch activities  
+ Reported SG&A impacted by increased 
charges for legal provisions, including a 
$425m charge to provisions relating to a 
legal settlement in Q3 2023 (see Note 6) 
∗ 
Core SG&A-to-Total Revenue ratio of 29%  
(Q3 2022: 29%) 
∗ Year-on-year comparisons can be impacted 
by differences in cost phasing 
Other 
operating 
income (and 
expense) 
22   
$70m -34% Actual      
-33% CER $70m -35% Actual      
-34% CER  
 
‒ Discontinuation of brazikumab development  
 
20   In Table 2, the plus and minus symbols denote the  directional impact of the item being discussed, e. g. a ‘+’ symbol next to an R&D 
expense comment indicates that the item increased the R&D expense relative to the prior year. 
21   Cost of goods sold. 
22   Income from disposals of assets and businesses, where the Group does not retain a significant ongoing economic interest, continue to 
be recorded in Other operating income and expense in the Company’s financial statements.

===== SIDA 5 =====

5 
Operating 
Margin 17% 
+6pp Actual      
+7pp CER 31% Stable at Actual      
+1pp CER  
 ∗ See Product Sales Gross Margin, 
expenses and Other operating income and 
expense commentary above 
Net finance 
expense  $291m -
9% Actual      
-6% CER $223m -12% Actual      
-7% CER  
 + Higher interest received on cash and short-
term investments, broadly offset by higher 
rates on floating debt and bond issuances  
Tax rate 17% n/m Actual      
n/m CER 19% +1pp Actual      
+1pp CER  
 ∗ Variations in the tax rate can be expected 
between periods 
EPS $0.89 -16% Actual      
-6% CER $1.73 4% Actual      
9% CER  
 ∗ Further details of differences between 
Reported and Core are shown in Table 14  
 
Table 3: Pipeline highlights since prior results announcement  
 
Event Medicine Indication / Trial Event 
Regulatory 
approvals and 
other 
regulatory 
actions 
Lynparza  mCRPC 
23  (1st-line) (PROpel)  Regulatory approval (JP)  
Enhertu  HER2m 24  NSCLC (2nd-line+) 
(DESTINY-Lung02)  
Positive CHMP Opinion (EU), 
Regulatory approval (EU, JP)  
Calquence  CLL 
25  (ASCEND)  Regulatory approval (CN)  
Forxiga  HFpEF 26  (DELIVER)  Regulatory approval (CN)  
Soliris  NMOSD  Regulatory approval (CN)  
Regulatory 
submissions  
or 
acceptances* 
Tagrisso  EGFR m NSCLC (1st-line) 
(FLAURA2)  
Regulatory submission (US, EU, 
CN), Priority Review (US)  
Imfinzi  NSCLC (neoadjuvant) (AEGEAN)  Regulatory submission (US)  
 capivasertib  HR+/HER2-negative breast cancer 
(2nd-line) (CAPItello-291) 
Regulatory submission (CN)  
 roxadustat Chemotherapy-induced anaemia Regulatory submission (CN) 
 FluMist  Self-administered influenza vaccine  Regulatory submission (US)  
Major Phase 
III data 
readouts and 
other 
developments 
Imfinzi  Liver cancer (locoregional) 
(EMERALD-1)  Primary endpoint met  
datopotamab 
deruxtecan  
HR+/HER2-breast cancer 
(inoperable and/or metastatic) 
(TROPION-Breast01)  
Primary endpoint met  
Fasenra  EGPA (MANDARA)  Primary endpoint met  
 
*US, EU and China regulatory submission denotes filing acceptance  
 
Upcoming pipeline catalysts 
 
For a table of anticipated timings of key trial rea douts, please refer to page 2 of the Clinical Trial s Appendix, 
available on www.astrazeneca.com/investor-relations.html .  
 
Other pipeline updates 
 
Ultomiris  discontinued plans to deliver subcutaneous adminis tration for adults with aHUS 27  or PNH 28 . This 
decision follows persistent efforts to reliably secure the availability of the on-body delivery system.  
 
Table 4: Phase III trials started since 1 January 2023 
 
Medicine Trial name Indication 
 
23   Metastatic castration-resistant prostate cancer. 
24   Human epidermal growth factor receptor mutant. 
25   Chronic lymphocytic leukaemia. 
26   Heart failure with preserved ejection fraction. 
27   Atypical haemolytic uraemic syndrome. 
28   Paroxysmal nocturnal haemoglobinuria.

===== SIDA 6 =====

6 
datopotamab 
deruxtecan  
AVANZAR  NSCLC (1st-line) 
TROPION-Lung07 Non-squamous NSCLC (1st-line) 
camizestrant  
CAMBRIA-1 HR-positive/HER2-negative adjuvant breast  cancer 
CAMBRIA-2 HR-positive/HER2-negative adjuvant breast  cancer 
capivasertib  CAPItello-292 HR-positive/HER2-negative advanced br east cancer 
volrustomig  
eVOLVE-Cervical High-risk locally advanced cervical  cancer 
eVOLVE-Lung02 mNSCLC (1st-line) with PD-L1 29  <50% 
zibo/dapa  ZENITH High Proteinuria CKD 30  and high proteinuria 
Saphnelo DAISY Systemic sclerosis 
Tezspire CROSSING Eosinophilic oesophagitis 
Breztri LITHOS Mild to moderate asthma 
Breztri  ATHLOS  COPD 31  
pMDI 32  portfolio HFO1234ze Mucociliary clearance in healt hy volunteers 
pMDI portfolio HFO1234ze Well-controlled or partial ly-controlled asthma 
tozorakimab MIRANDA Symptomatic COPD 
AZD3152  SUPERNOVA COVID-19 prophylaxis 
Ultomiris  ARTEMIS  Cardiac surgery-associated acute kidney injury 
 
Corporate and business development 
 
In September, AstraZeneca and Verge Genomics (Verge ) announced a multi-target collaboration to identif y 
novel drug targets for rare neurodegenerative and n euromuscular diseases. Verge is a clinical-stage dr ug 
discovery company using artificial intelligence and  patient tissue data. Under the terms of the four-y ear 
agreement, Verge will receive up to $42 million, consisting of upfront fee, equity, and near-term payments, with 
potential downstream royalties. AstraZeneca will take an equity position in Verge.  
 
In September, AstraZeneca completed the definitive purchase and licence agreement for a portfolio of 
preclinical rare disease gene therapy programmes an d enabling technologies from Pfizer Inc. The agreement 
has a total consideration of up to $1bn, plus tiered royalties on sales.  
 
Cellectis 
 
In November, AstraZeneca announced a collaboration and investment agreement with Cellectis, a clinical-stage 
biotechnology company, to accelerate the developmen t of next generation therapeutics in areas of high unmet 
need, including oncology, immunology and rare disea ses. Under the terms of the collaboration agreement , 
AstraZeneca will leverage the Cellectis proprietary gene editing technologies and manufacturing capabilities, to 
design novel cell and gene therapy products, streng thening AstraZeneca's growing offering in this spac e. As 
part of the agreement, 25 genetic targets have been exclusively reserved for AstraZeneca, from which up to 10 
candidate products could be explored for development.  
 
In Q4 2023, Cellectis will receive an initial payme nt of $105m from AstraZeneca, which comprises a $25 m 
upfront cash payment under the terms of a research collaboration agreement and an $80m equity investme nt. 
A further $140m equity investment is expected to cl ose in early 2024 subject to the signing of a final  binding 
agreement. Post-closing of this second investment, AstraZeneca will hold a total equity stake of appro ximately 
44% in Cellectis. Under the terms of the research c ollaboration, Cellectis is also eligible to receive  an 
investigational new drug option fee and development, regulatory and sales-related milestone payments, ranging 
from $70m up to $220m, per each of the 10 candidate products, plus tiered royalties. 
 
Eccogene licence 
 
 
29   Programmed death-ligand 1. 
30   Chronic kidney disease. 
31   Chronic obstructive pulmonary disease. 
32   Pressure metered dose inhaler.

===== SIDA 7 =====

7 
In November, AstraZeneca and Eccogene entered into an exclusive licence agreement for ECC5004, an 
investigational oral once-daily glucagon-like peptide 1 receptor agonist (GLP-1RA) for the treatment of obesity, 
type-2 diabetes and other cardiometabolic conditions . Preliminary results from the Phase I trial have s hown a 
differentiating clinical profile for ECC5004, with good tolerability and encouraging glucose and body weight 
reduction across the dose levels tested compared to placebo. 
 
Under the terms of the agreement, Eccogene will rec eive an initial upfront payment of $185m and up to an 
additional $1.825bn in future clinical, regulatory,  and commercial milestones and tiered royalties. As traZeneca 
is granted exclusive global rights for the developm ent and commercialisation of ECC5004 for any indica tion in 
all territories except China, where Eccogene has th e right to co-develop and co-commercialise alongsid e 
AstraZeneca. 
 
Sustainability summary 
 
This quarter AstraZeneca entered into long-term ren ewable energy partnerships in the UK and Sweden. Th e 
UK agreement will support the transition away from fossil fuels at Company sites in Macclesfield, Camb ridge, 
Luton and Speke. The Sweden agreement corresponds to approximately 80 percent of total electricity needs at 
both the Company's Gothenburg site and at Södertälj e, one of the world's largest drug manufacturing ce ntres. 
See the Sustainability section for further details.  
 
Conference call  
 
A conference call and webcast for investors and analysts will begin today, 9 November 2023, at 14:00 UK time. 
Details can be accessed via astrazeneca.com. 
 
Reporting calendar  
 
The Company intends to publish its full year and fourth quarter results on Thursday 8 February 2024. 
 
Operating and financial review 
 
All narrative on growth and results in this section is based on actual foreign exchange rates, and financial figures 
are in US$ millions ($m), unless stated otherwise. The performance shown in this announcement covers t he 
nine-month period to 30 September 2023 (‘the period ' or ‘9M 2023') compared to the nine-month period t o 30 
September 2022 (‘9M 2022'), or the three-month peri od to 30 September 2023 (‘the quarter' or ‘Q3 2023' ) 
compared to the three-month period to 30 September 2022 (‘Q3 2022'), unless stated otherwise. 
 
Core financial measures, EBITDA, Net debt, Product Sales Gross Margin (formerly termed as Gross Margin ), 
Operating Margin and CER are non-GAAP financial measures because they cannot be derived directly from the 
Group's Interim financial statements. Management be lieves that these non-GAAP financial measures, when  
provided in combination with Reported results, prov ide investors and analysts with helpful supplementa ry 
information to understand better the financial perf ormance and position of the Group on a comparable b asis 
from period to period. These non-GAAP financial mea sures are not a substitute for, or superior to, fin ancial 
measures prepared in accordance with GAAP.  
 
Core financial measures are adjusted to exclude certain significant items, such as:  
 
‒ Amortisation and impairment of intangible assets, including impairment reversals but excluding any charges 
relating to IT assets 
 
‒ Charges and provisions related to restructuring pr ogrammes, which includes charges that relate to the impact 
of restructuring programmes on capitalised IT assets 
 
‒ Alexion acquisition-related items, primarily fair value adjustments on acquired inventories and fair value 
impact of replacement employee share awards 
 
‒ Other specified items, principally the imputed fin ance charges and fair value movements relating to 
contingent consideration on business combinations o r asset acquisitions, imputed finance charges and 
remeasurement adjustments on certain Other payables  arising from intangible asset acquisitions, legal 
settlements and remeasurement adjustments relating to Other payables assumed from the Alexion 
acquisition 
 
‒ The tax effects of the adjustments above are exclu ded from the Core Tax charge

===== SIDA 8 =====

8 
Details on the nature of Core financial measures are provided on page 63 of the Annual Report and Form 20-F 
Information 2022 .  
 
Reference should be made to the Reconciliation of R eported to Core financial measures table included i n the 
financial performance section in this announcement. 
 
Product Sales Gross Margin (formerly termed Gross Margin) is the percentage by which Product Sales exceeds 
the Cost of Sales, calculated by dividing the diffe rence between the two by the sales figure. The calc ulation of 
Reported and Core Product Sales Gross Margin exclud es the impact of Alliance Revenue and Collaboration  
Revenue and any associated costs, thereby reflecting the underlying performance of Product Sales. 
 
EBITDA is defined as Reported Profit before tax aft er adding back Net finance expense, results from Jo int 
ventures and associates and charges for Depreciation, amortisation and impairment. Reference should be made 
to the Reconciliation of Reported Profit before tax  to EBITDA included in the financial performance se ction in 
this announcement. 
 
Operating Margin is defined as Operating profit as a percentage of Total Revenue. 
 
Net debt is defined as Interest-bearing loans and b orrowings and Lease liabilities, net of Cash and ca sh 
equivalents, Other investments, and Net derivative financial instruments. Reference should be made to Note 3 
‘Net debt' included in the Notes to the Interim financial statements in this announcement. 
 
The Company strongly encourages investors and analy sts not to rely on any single financial measure, bu t to 
review AstraZeneca's financial statements, includin g the Notes thereto, and other available Company re ports, 
carefully and in their entirety. 
 
Due to rounding, the sum of a number of dollar values and percentages in this announcement may not agree to 
totals. 
 
Total Revenue 
 
Table 5: Therapy area and medicine performance - Product Sales and Total Revenue 
 
  9M 2023  Q3 2023 
    % Change    % Change 
Product Sales   $m  % Total  Actual  CER  $m  % Total  Actual  CER  
Oncology   12,692  38  17  20  4,389  38  16  17  
- Tagrisso   4,380  13  7  10  1,465  13  5  6  
- Imfinzi 33   3,102  9  53  56  1,126  10  53  54  
- Lynparza   2,070  6  6  9  702  6  7  8  
- Calquence   1,839  5  25  26  654  6  16  15  
- Enhertu   178  1  >3x  >3x  73  1  >3x  >3x  
- Orpathys   33  -   (3)  4  12  -  6  13  
- Zoladex   699  2  (3)  5  239  2  -  5  
- Faslodex   217  1  (16)  (10)  64  1  (21)  (16)  
- Others   174  1  (36)  (32)  54  -  (33)  (30)  
BioPharmaceuticals: CVRM  7,887  23  14  18  2,683  23  14  16  
- Farxiga   4,358  13  36  40  1,554  14  41  41  
- Brilinta   996  3  (2)  - 331  3  (2)  (1)  
- Lokelma   300  1  44  49  102  1  30  31  
- roxadustat   208  1  41  51  74  1  31  39  
- Andexxa   129  -   16  19  40  -  (3)  (5)  
- Crestor   860  3  4  11  275  2  (1)  6  
- Seloken/Toprol-XL   496  1  (30)  (23)  153  1  (36)  (29)  
- Onglyza  180  1  (12)  (8)  53  -  (20)  (17)  
- Bydureon   123  -   (40)  (40)  35  -  (48)  (49)  
- Others   237  1  (16)  (13)  66  1  (23)  (21)  
BioPharmaceuticals: R&I   4,517  13  5  8  1,451  13  2  3  
- Symbicort   1,842  5  (4)  (1)  555  5  (12)  (10)  
- Fasenra    1,134  3  12  13  389  3  10  10  
- Breztri    478  1  69  73  171  1  66  69  
 
33  Product Sales shown in the Imfinzi line include Product Sales from Imjudo.

===== SIDA 9 =====

9 
- Saphnelo   191  1  >2x  >2x  76  1  >2x  >2x  
- Tezspire   51  -   >10x  >10x  21  -  >10x  >10x  
- Pulmicort   493  1  3  10  148  1  2  7  
- Bevespi   42  -   (2)  (2)  13  -  (5)  (4)  
- Daliresp/Daxas    41  -   (74)  (74)  11  -  (79)  (79)  
- Others   245  1  (30)  (27)  67  1  (31)  (28)  
BioPharmaceuticals: V&I   667  2  (82)  (81)  224  2  (74)  (74)  
- COVID-19 mAbs 34   126  -   (91)  (90)  -  -  n/m  n/m  
- Vaxzevria    28  -   (98)  (98)  -  -  n/m  n/m  
- Beyfortus   52  -   n/m  n/m  50  -  n/m  n/m  
- Synagis   383  1  -  6  99  1  (5)  (1)  
- FluMist    78  -   32  28  75  1  28  23  
Rare Disease  5,793  17  11  12  1,974  17  13  14  
- Soliris   2,429  7  (17)  (15)  781  7  (13)  (12)  
- Ultomiris    2,141  6  56  58  777  7  50  49  
- Strensiq    847  3  23  24  285  2  20  21  
- Koselugo   246  1  65  65  87  1  81  81  
- Kanuma    130  -   17  18  44  -   21  19  
Other Medicines   910   3  (27)  (22)  297   3  (27)  (22)  
- Nexium   735  2  (25)  (20)  244  2  (22)  (17) 
- Others  175  1  (33)  (31)  53  -   (43)  (41)  
Product Sales   32,466   96   1  4  11,018   96   4  5  
Alliance Revenue  1,004  3  99  99  377  3  76  75  
Collaboration Revenue   317  1  (28)  (28)  97  1  (46)  (47)  
Total Revenue  33,787   100   2  5  11,492   100   5  6  
 
Table 6: Alliance Revenue 
  9M 2023 Q3 2023 
    % Change    % Change 
  $m  % Total  Actual  CER  $m  % Total  Actual  CER  
Enhertu  741  74  >2x  >2x  266  70  66  65  
Tezspire  179  18  >4x  >4x  74  20  >2x  >2x  
Vaxzevria : royalties  -  -  n/m  n/m  -  -  n/m  n/m  
Other royalty income  59  6  16  15  18  5  10  9  
Other Alliance Revenue   25  2  >2x  >2x  19  5  >3x  >3x  
Total   1,004  100  99  99  377  100  76  75  
 
Table 7: Collaboration Revenue 
  9M 2023 Q3 2023 
 
    % Change    % Change 
  $m  % Total  Actual  CER  $m  % Total  Actual  CER  
COVID-19 mAbs: licence fees  180  57  n/m  n/m  -  -  n/m  n/m  
Farxiga : sales milestones   28  9  n/m  n/m  3  3  n/m  n/m  
tralokinumab: sales milestones   20  6  (82)  (82)  20  21  (50)  (50)  
Lynparza : regulatory milestones   -  -  n/m  n/m  -  -  n/m  n/m  
Beyfortus : regulatory milestones   71  22  n/m  n/m  71  73  n/m  n/m  
Other Collaboration Revenue   18  6  (76)  (76)  3  3  (95)  (95)  
Total   317  100  (28)  (28)  97  100  (46)  (47)  
 
Table 8: Total Revenue by therapy area 
 
  9M 2023 Q3 2023 
 
    % Change    % Change 
  $m  % Total  Actual  CER  $m  % Total  Actual  CER  
Oncology   13,458  40  17  20  4,664  41  15  17  
BioPharmaceuticals  13,599  40  (10)  (7)  4,548  40  (4)  (2)  
 
34  COVID-19 monoclonal antibodies.

===== SIDA 10 =====

10 
- CVRM   7,926  23  14  19  2,687  23  14  16  
- R&I   4,729  14  6  9  1,549  13  3  5  
- V&I   944  3  (74)  (73)  312  3  (64)  (65)  
Rare Disease  5,793  17  11  12  1,974  17  13  14  
Other Medicines  
 
937  3  (30)  (26)  306  3  (36)  (32)  
Total  
 
33,787   100   2  5  11,492   100   5  6  
 
Table 9: Total Revenue by region 
 
  9M 2023   Q3 2023 
     % Change     % Change 
  $m  % Total   Actual  CER  $m  % Total   Actual  CER  
US  13,940  41  6  6  4,859  42  5  4  
Emerging Markets   9,242  27  3  10  2,964  26  4  12  
- China   4,495  13  (2)  5  1,452  13  (6)  1  
- Ex-China   4,747  14  8  15  1,513  13  15  25  
Europe   6,765  20  5  5  2,392  21  16  9  
Established RoW   3,840  11  (16)  (9)  1,276  11  (10)  (6)  
Total   33,787  100  2  5  11,492  100  5  6  
 
Table 10: Total Revenue by region - excluding COVID-19 medicines 
 
  9M 2023  Q3 2023 
     % Change     % Change 
  $m  % Total   Actual  CER  $m  % Total   Actual  CER  
US  13,940  42  14  14  4,859  42  12  12  
Emerging Markets   9,038  27  12  20  2,964  26  8  16  
- China   4,495  13  (1)  6  1,452  13  (6)  1  
- Ex-China   4,544  14  28  37  1,513  13  25  36  
Europe   6,748  20  14  14  2,392  21  23  16  
Established RoW   3,726  11  -  8  1,276  11  5  10  
Total   33,453  100  12  15  11,492  100  12  13  
 
Oncology 
 
Oncology Total Revenue of $13,458m in 9M 2023 increased by 17% (20% at CER), representing 40% of overall 
Total Revenue (9M 2022: 35%). There was no Lynparza  Collaboration Revenue in 9M 2023 (9M 2022: $250m), 
and Enhertu  Alliance Revenue was $741m (9M 2022: $335m). Product Sales increased by 17% (20% at CER) 
in 9M 2023 to $12,692m, reflecting new launches and  expanded reimbursement across key brands; partiall y 
offset by declines in legacy medicines. 
 
Tagrisso 
 
Total Revenue Worldwide  US Emerging Markets  Europe Established RoW  
9M 2023  $m 4,380   1,679  1,261  821  619  
Actual change  7%  14% 4% 6% (4%) 
CER change  10%  14% 11% 6% 5% 
 
Region   Drivers and commentary 
Worldwide  ∗ Increased global demand for Tagrisso in adjuvant and 1st-line settings combined with 
expanded reimbursement in the adjuvant setting 
US  ∗ Continued growth in demand in 1st-line and adjuvant settings  
Emerging Markets  ∗ Growing demand in adjuvant and 1st-line settings offset by impact of NRDL 35  renewal 
price in China effective March 2023, some additional impact in China in the third quarter 
resulting from reduced promotional activities following the government campaign 
announced at the end of July 2023 
 
35  National reimbursement drug list.

===== SIDA 11 =====

11 
Europe  ∗ Increased demand growth in 1st-line and growing adjuvant demand    
Established RoW  ∗ Increased demand in 1st-line and adjuvant settings offset by mandatory price reduction in 
Japan effective June 2023 
 
Imfinzi and  Imjudo  
 
Total Revenue Worldwide  US Emerging Markets  Europe Established RoW  
9M 2023  $m 3,102  1,708  270  547  577  
Actual change  53%   55%  20%  36%  90%  
CER change  56%   55%  31%  35%  >2x  
 
Region   Drivers and commentary 
Worldwide  ∗ Includes $161m of Total Revenue from Imjudo, which launched in Q4 2022 following 
approvals in the US for patients with unresectable liver cancer (HIMALAYA) and Stage IV 
NSCLC (POSEIDON)  
∗ Growth across all regions, driven by recent launches (BTC 36 , HCC 37 , Stage IV NSCLC) 
and established indications (Stage III NSCLC, SCLC 38 ) 
US  ∗ Continued demand growth for BTC and HCC indications, increased uptake in SCLC 
Emerging Markets  ∗ Growth across markets driven by BTC launches and recovery of diagnosis and treatment 
rates following the COVID-19 pandemic, slightly offset by decreased promotional activities 
in China due to the government campaign announced at the end of July 2023 
Europe  ∗ Competitive share gain in SCLC, and expanded reimbursement for new launch indications 
(BTC, HCC and Stage IV NSCLC) 
Established RoW  ∗ Growth driven by launch of HCC and BTC and increased share across indications in 
Japan 
 
Lynparza 
 
Total Revenue Worldwide  US Emerging Markets  Europe Established RoW  
9M 2023  $m 2,070   902  409  543  216  
Actual change  (6%)  1% 14% (27%) 7% 
CER change  (3%)  1% 24% (27%) 16% 
 
Product Sales Worldwide  US Emerging Markets  Europe Established RoW  
9M 2023  $m 2,070   902  409  543  216  
Actual change  6%  1% 14% 10% 7% 
CER change  9%  1% 24% 10% 16% 
 
Region   Drivers and commentary 
Worldwide  ∗ Lynparza remains the leading medicine in the PARP 39  inhibitor class globally across four 
tumour types (ovarian, breast, prostate, pancreatic), as measured by total prescription 
volume 
∗ No regulatory milestones received in the period 
US  ∗ Continued share growth within the PARP inhibitor class, offset by declining class use and 
the label restriction in 2nd-line ovarian cancer effective September 2023  
Emerging Markets  ∗ Increased demand, offset by price reduction in China associated with NRDL renewal that 
took effect March 2023 for ovarian cancer indications (PSR 40  and BRCAm 41  1st-line 
maintenance) and new NRDL enlistment in prostate cancer (PROfound) as well as some 
impact in the third quarter resulting from reduced promotional activities following the 
government campaign announced end of July 2023 
 
36  Biliary tract cancer. 
37  Hepatocellular carcinoma. 
38  Small cell lung cancer. 
39  Poly ADP ribose polymerase. 
40  Platinum sensitive relapse. 
41  Breast cancer gene mutation.

===== SIDA 12 =====

12 
Europe  ∗ Demand growth from increased uptake in 1st-line HRD-positive ovarian cancer, 
gBRCAm 42  HER2-negative early breast cancer and mCRPC, offset by reduced use in 2nd-
line ovarian cancer and pricing  
∗ Total Revenue in the prior year period included $250m of milestones  
Established RoW  ∗ Growth driven by increased uptake in testing and use in 1st-line HRD-positive ovarian 
cancer  
 
 
Enhertu 
 
Total Revenue Worldwide  US Emerging Markets  Europe Established RoW  
9M 2023  $m 919   518  179  204  17  
Actual change  >2x   >2x  >3x  >2x  >3x  
CER change  >2x   >2x  >3x  >2x  >3x  
 
Region   Drivers and commentary 
Worldwide  ∗ Combined sales of Enhertu , recorded by Daiichi Sankyo Company Limited (Daiichi 
Sankyo) and AstraZeneca, amounted to $1,844m in 9M 2023 (9M 2022: $750m) 
∗ AstraZeneca's Total Revenue of $919m in the period includes $741m of Alliance Revenue 
from its share of gross profit and royalties in territories where Daiichi Sankyo records 
product sales 
US  ∗ US in-market sales, recorded by Daiichi Sankyo, amounted to $1,087m in 9M 2023 (9M 
2022: $532m)  
∗ Increased demand across launched indications. Q3 2023 impacted by HER2-low bolus 
depletion  
Emerging Markets  ∗ Continued uptake driven by recent approvals and launches including strong demand 
growth in China following HER2-positive and HER2-low breast cancer launches 
Europe  ∗ Continued growth driven by increasing adoption in HER2-positive and HER2-low 
metastatic breast cancer  
Established RoW  ∗ In Japan, AstraZeneca receives a mid-single-digit percentage royalty on sales made by 
Daiichi Sankyo 
 
Calquence  
 
Total Revenue Worldwide  US Emerging Markets  Europe Established RoW  
9M 2023  $m 1,839   1,337  69  353  80  
Actual change  25%  12% >2x  76% 64% 
CER change  26%  12% >2x  77% 74% 
 
Region   Drivers and commentary 
Worldwide  ∗ Increased penetration globally; leading BTKi 43  in key markets  
US  ∗ Leadership maintained in growing BTKi class, sustained leading share in the front-line 
setting, offset by some competitive impact in relapsed refractory setting and increased 
utilisation of free goods program in Q3 
EU  ∗ Solid growth continued amidst growing competitive pressure 
∗ Increased new patients starts following expanded access in key markets 
 
Orpathys 
 
Orpathys Total Revenue of $34m declined 1% (6% incr ease at CER), (9M 2022: $35m), following its inclus ion 
in the updated NRDL in China from March 2023, for t he treatment of patients with NSCLC with MET exon 1 4 
skipping alterations.  
 
Other Oncology medicines  
 
 9M 2023 Change  
 
 
42  Germline (hereditary) breast cancer gene mutation. 
43  Bruton tyrosine kinase inhibitor.

===== SIDA 13 =====

13 
Total Revenue  $m Actual CER  
Zoladex  723 (2%) 5% ∗ Underlying growth due to continued demand growth in Emerging 
Markets, partially offset by price reduction in China following 
NRDL renewal 
Faslodex  217 (16%) (10%) ∗ Generic competition  
Other Oncology  174  (36%)  (32%)  ∗ Generic competition 
 
 
BioPharmaceuticals 
 
BioPharmaceuticals Total Revenue decreased by 10% (7% at CER) in 9M 2023 to $13,599m, representing 40% 
of overall Total Revenue (9M 2022: 45%). The declin e was driven by COVID-19 medicines, partially offse t by 
strong growth  from Farxiga and newer R&I medicines . 
 
BioPharmaceuticals - CVRM 
 
CVRM Total Revenue increased by 14% (19% at CER) to  $7,926m in 9M 2023, driven by the strong Farxiga  
performance, and represented 23% of overall Total Revenue (9M 2022: 21%). 
 
Farxiga 
 
Total Revenue Worldwide  US Emerging Markets  Europe Established RoW  
9M 2023  $m 4,389   1,000  1,655  1,356  378  
Actual change  37%  34% 35% 42% 35% 
CER change  41%  34% 43% 41% 45% 
 
Region   Drivers and commentary 
Worldwide 
 
 ∗ Farxiga  volume is growing faster than the overall SGLT2 44  market in most major regions, 
fuelled by launches in heart failure and CKD 
∗ Additional benefit from continued growth in the overall SGLT2 inhibitor class 
US  ∗ Growth driven by heart failure and CKD for patients with and without T2D 45  resulting in an 
increasing market share 
Emerging Markets  ∗ Solid growth despite generic competition in some markets  
Europe  ∗ Benefited from the addition of cardiovascular outcomes trial data to the label and growth in 
HFrEF 46 , CKD and the HFpEF approval in February 2023. ESC 47  guidelines updated in 
August 2023 to also include treatment of patients with HFpEF 
∗ Continued strong volume growth in the quarter and expanded class leadership in several 
key markets 
Established RoW  ∗ In Japan, AstraZeneca sells to collaborator Ono Pharmaceutical Co., Ltd, which records 
in-market sales. Continued volume growth driven by HF and CKD launches. Generics 
launched in Canada in the third quarter 
 
Brilinta 
 
Total Revenue Worldwide  US Emerging Markets  Europe Established RoW  
9M 2023  $m 996   551  224  203  18  
Actual change  (2%)  2% 1% (5%) (54%) 
CER change  -  2% 10% (5%) (51%) 
 
Region   Drivers and commentary 
US  ∗ Sales in the third quarter benefitted from channel inventory movements  
Emerging Markets  ∗ Sales declined by 16% (4% at CER) in the third quarter driven by tender phasing 
Europe  ∗ Sales partly impacted by clawbacks 
 
44  Sodium-glucose cotransporter 2. 
45  Type-2 diabetes. 
46  Heart failure with reserved ejection fraction. 
47  European Society of Cardiology.

===== SIDA 14 =====

14 
Established RoW  ∗ Sales decline driven by generic entry in Canada 
 
Lokelma 
 
Lokelma Total Revenue increased 44% (49% at CER) to $300m  with strong demand growth in all regions. 
 
Roxadustat 
 
Total Revenue increased 40% (50% at CER) to $212m, benefitting from increased demand in both the dialysis- 
and non-dialysis-dependent populations 
 
Andexxa 
 
Andexxa  Total Revenue increased 7% (9% at CER) to $129m.  
 
Other CVRM medicines 
 
 9M 2023 Change  
 
Total Revenue  $m Actual CER  
Crestor  862 4% 11% ∗ Continued sales growth in Emerging Markets, partly offset by 
declines in the US and Established RoW 
Seloken  496 (30%) (23%) ∗ Ongoing impact of China VBP implementation  
Onglyza  180 (12%) (8%) ∗ Continued decline for DPP-IV class  
Bydureon  123 (40%) (40%) ∗ Continued competitive pressures 
Other CVRM  237 (16%) (13%)  
 
BioPharmaceuticals - R&I  
 
Total Revenue of $4,729m from R&I medicines in 9M 2 023 increased 6% (9% at CER) and represented 14% 
of overall Total Revenue (9M 2022: 14%). This refle cted growth in Fasenra , Tezspire , Breztri  and Saphnelo, 
offsetting  a decline in Symbicort and other mature brands . 
 
Fasenra  
 
Total Revenue Worldwide  US Emerging Markets  Europe Established RoW  
9M 2023  $m 1,134   718  48  262  106  
Actual change  12%  11% 62% 14% (1%) 
CER change  13%  11% 69% 14% 6% 
  
Region   Drivers and commentary 
Worldwide  ∗ Retained market share leadership in severe eosinophilic asthma across major markets  
US  ∗ Expanded leadership in eosinophilic asthma and maintained total share in a growing 
market, leading to double-digit volume growth, partially offset by managed market price 
difference 
Emerging Markets  ∗ Continued strong volume growth driven by launch acceleration across key markets  
Europe  ∗ Expanded leadership in severe eosinophilic asthma, with strong volume growth partially 
offset by price in some markets  
Established RoW  ∗ Maintained class leadership in Japan while market growth remained stable 
 
Breztri 
 
Total Revenue Worldwide  US Emerging Markets  Europe Established RoW  
9M 2023  $m 478   263  123  55  37  
Actual change  69%  60% 73% >2x  48% 
CER change  73%  60% 86% >2x  58% 
 
Region   Drivers and commentary

===== SIDA 15 =====

15 
Worldwide  ∗ Continued to gain market share within the growing FDC 48  triple class across major markets  
US  ∗ Consistent share growth within the FDC triple class in new-to-brand 49  and the total market 
Emerging Markets  ∗ Maintained market share leadership in China with strong triple FDC class penetration  
Europe  ∗ Sustained growth across markets as new launches continue to progress  
Established RoW  ∗ Increased market share gains within COPD in Japan and strong launch performance in 
Canada  
 
Tezspire 
 
Total Revenue Worldwide  US Emerging Markets  Europe Established RoW  
9M 2023  $m 230   179  - 28  23  
Actual change  >5x   >4x  - n/m  n/m  
CER change  >5x   >4x  - n/m  n/m  
 
Region   Drivers and commentary 
Worldwide  ∗ Tezspire  is approved in the US, EU and Japan (as well as other countries) for the 
treatment of severe asthma without biomarker or phenotypic limitation 
∗ Amgen records sales in the US, and AstraZeneca records its share of US gross profits as 
Alliance Revenue. AstraZeneca books Product Sales in markets outside the US 
∗ Combined sales of Tezspire  by AstraZeneca and Amgen were $438m in 9M 2023 
US   ∗ Increased new-to-brand market share with majority of patients new to biologics 
∗ Pre-filled pen approved in February 2023  
Europe   ∗ Achieved and maintained new-to-brand leadership in key markets 
∗ Pre-filled pen approved in January 2023  
Established RoW  ∗ Japan maintained new-to-brand leadership 
 
Saphnelo  
 
Total Revenue Worldwide  US Emerging Markets  Europe Established RoW  
9M 2023  $m 191   178  1  5  7  
Actual change  >2x   >2x  n/m >4x  >3x  
CER change  >2x   >2x  n/m >4x  >3x  
 
Region   Drivers and commentary 
Worldwide  ∗ Demand acceleration in the US, and additional growth driven by ongoing launches in 
Europe and Japan  
 
Symbicort 
 
Total Revenue Worldwide  US Emerging Markets  Europe Established RoW  
9M 2023  $m 1,842   589  600  408  245  
Actual change  (4%)  (18%) 26% (8%) (12%) 
CER change  (1%)  (18%) 36% (8%) (7%) 
 
Region   Drivers and commentary 
Worldwide  ∗ Symbicort  remained the global market leader within a stable ICS 50 /LABA 51  class  
US  ∗ Generic competition entered the US market in the third quarter, leading to price and 
volume share declines  
Emerging Markets  ∗ Strong underlying demand. Growth in China benefitted from the post-COVID-19 recovery 
at the start of the year 
Europe   ∗ Continued price and volume erosion from generics and a slowing overall market   
 
48  Fixed dose combination. 
49  ‘New-to-brand’ share represents a medicine’s share in the dynamic market. 
50  Inhaled corticosteroid. 
51  Long-acting beta-agonist.

===== SIDA 16 =====

16 
Established RoW  ∗ Generic erosion in Japan  
 
Other R&I medicines  
 
 9M 2023    Change  
 
Total Revenue  $m Actual CER  
Pulmicort  493 3% 10% ∗ 80% of revenues from Emerging Markets  
∗ China market share has stabilised, with VBP having been in effect 
for over 12 months 
Bevespi  42 (2%) (2%)  
Daliresp  41 (74%) (74%) ∗ Impacted by uptake of multiple generics following loss of 
exclusivity in the US  
Other R&I   278 (41%) (38%) ∗ Collaboration Revenue of $20m (9M 2022: $110m) 
∗ Product Sales of $245m decreased 30% (27% at CER) due to 
generic competition 
 
BioPharmaceuticals - V&I  
 
Total Revenue from V&I medicines declined by 74% (7 3% at CER) to $944m (9M 2022: $3,673m) and 
represented 3% of overall Total Revenue (9M 2022: 1 1%). In Q3 2023, no revenue was generated from 
COVID-19 medicines.  
 
COVID-19 mAbs 
 
Total Revenue Worldwide  US Emerging Markets  Europe Established RoW  
9M 2023  $m 306   -  185  7  114  
Actual change  (79%)  n/m 11% (97%) (51%) 
CER change  (78%)  n/m 11% (96%) (45%) 
 
Region   Drivers and commentary 
Worldwide  ∗ All Product Sales in 9M 2023 were derived from sales of Evusheld  in the first quarter  
Emerging Markets  ∗ $180m license fee from Serum Institute of India in Q2 2023 recorded as Collaboration 
Revenue  
 
 
Vaxzevria 
 
Total Revenue Worldwide  US Emerging Markets  Europe Established RoW  
9M 2023  $m 28   -  18  10  -  
Actual change  (98%)  n/m (98%) (97%) n/m 
CER change  (98%)  n/m (98%) (97%) n/m 
 
Region   Drivers and commentary 
Worldwide  ∗ Revenue in the period decreased by 98% due to the conclusion of Vaxzevria contracts 
 
Other V&I medicines  
 
 9M 2023 Change  
 
Total Revenue  $m Actual CER  
Beyfortus  139 n/m n/m ∗ In Q3 2023 AstraZeneca reported $50m of Product Sales, $17m 
of Alliance Revenue , and also $71m of Collaboration Revenue 
relating to a regulatory milestone 
∗ The Product Sales relates to sales to Sanofi of Beyfortus  product 
manufactured by AstraZeneca. In Q3 Product Sales benefitted 
from stock building for the 2023-2024 RSV 52  season 
∗ The Alliance Revenue consists of AstraZeneca's 50% share of 
gross profits on sales of Beyfortus  in major markets outside the 
 
52  Respiratory syncytial virus.

===== SIDA 17 =====

17 
US. AstraZeneca will also book 25% of revenues in rest of world 
markets. AstraZeneca has no participation in US profits or losses 
Synagis  383 - 6% ∗ Performance broadly in-line with prior year  
FluMist  88 49% 45% ∗ $10m milestone received from Daiichi Sankyo in the second 
quarter following FluMist approval in Japan 
 
Rare Disease 
 
Total Revenue from Rare Disease medicines increased  by 11% (12% at CER) in 9M 2023 to $5,793m, 
representing 17% of overall Total Revenue (9M 2022: 16%). 
 
Performance was driven by the continued growth and durability of the C5 53  franchise, and also the strength of 
Strensiq and Koselugo  patient demand.  
 
Ultomiris 
 
Total Revenue Worldwide  US Emerging Markets  Europe Established RoW  
9M 2023  $m 2,141   1,260  47  495  339  
Actual change  56%  63% 38% 43% 54% 
CER change 58%  63% 39% 42% 68% 
 
Region   Drivers and commentary 
Worldwide  ∗ Growth in neurology indications, expansion into new markets and continued conversion 
from Soliris   
∗ Quarter-on-quarter variability in revenue growth can be expected due to Ultomiris  every 
eight-week dosing schedule and lower average annual treatment cost per patient 
compared to Soliris  
US  ∗ Growth in naïve patients in gMG 54  and NMOSD as well as successful conversion from 
Soliris across shared indications 
Emerging Markets  ∗ Continued progress following launches in new markets  
Europe  ∗ Strong demand generation following launches in new markets, particularly in neurology 
indications, as well as accelerated conversion from Soliris  in key markets  
Established RoW  ∗ Continued conversion from Soliris and strong demand following new launches, particularly 
NMOSD in Japan 
 
 
Soliris  
 
Total Revenue Worldwide  US Emerging Markets  Europe Established RoW  
9M 2023  $m 2,429   1,313  338  530  248  
Actual change  (17%)  (22%) 55% (15%) (36%) 
CER change (15%)  (22%) 74% (15%) (31%) 
 
Region   Drivers and commentary 
US  ∗ Decline driven by successful conversion of Soliris  patients to Ultomiris  in PNH, aHUS and 
gMG, partially offset by Soliris growth in NMOSD 
Emerging Markets  ∗ Continued progress, launching in new markets  
Europe,  
Established RoW 
 ∗ Decline driven by successful conversion from Soliris  to Ultomiris , partially offset by growth 
in NMOSD  
 
Strensiq 
 
Total Revenue Worldwide  US Emerging Markets  Europe Established RoW  
9M 2023  $m 847   690  29  64  64  
Actual change  23%  26% 14% 9% 12% 
CER change 24%  26% 16% 8% 22% 
 
53  Complement component 5. 
54  Generalised myasthenia gravis.

===== SIDA 18 =====

18 
 
Region   Drivers and commentary 
Worldwide  ∗ Strong patient demand particularly in the US and Japan  
 
Other Rare Disease medicines  
 
 9M 2023 Change  
 
Total Revenue  $m Actual CER Commentary 
Koselugo  246 65% 65% ∗ Driven by patient demand and expansion in new markets  
Kanuma  130 17% 18% ∗ Continued demand growth in ex-US markets 
 
Other medicines (outside the main therapy areas) 
 
 9M 2023 Change  
 
Total Revenue  $m Actual CER Commentary 
Nexium  748 (30%) (25%) ∗ Generic launches in Japan in the latter part of 2022 
Others   189 (31%) (29%) ∗ Continued impact of generic comp etition 
 
Financial performance 
 
Table 11: Reported Profit and Loss 
 
  9M 2023  9M 2022  % Change  Q3 2023  Q3 2022  % Change 
 
  $m  $m  Actual   CER  $m  $m  Actual   CER   
Total Revenue  33,787  33,144  2  5  11,492  10,982  5  6  
- Product Sales  32,466  32,200  1  4  11,018  10,590  4  5  
- Alliance Revenue  1,004  504  99  99  377  214  76  75  
- Collaboration Revenue  317  440  (28) (28) 97  178  (46)  (47)  
Cost of sales  (5,960) (9,491) (37) (38) (2,095) (2,982) (30) (31) 
Gross profit  27,827  23,653  18  22  9,397  8,000  17  20  
Product Sales Gross Margin  81.6%  70.5%  +11pp  +12pp  81.0%  71.8%  +9pp  +10pp  
Distribution expense  (394) (380) 4  6  (129) (126) 2  2  
% Total Revenue  1.2%  1.1%  -  -  1.1%  1.1%  -  -  
R&D expense  (7,862) (7,137) 10  12  (2,584) (2,458) 5  4  
% Total Revenue  23.3%  21.5%  -2pp  -2pp  22.5%  22.4%  -  -  
SG&A expense  (13,845)  (13,798)  -  2  (4,800) (4,277) 12  12  
% Total Revenue  41.0%  41.6%  +1pp  +1pp  41.8%  38.9%  -3pp  -2pp  
OOI 55  & expense  1,233  325  >3x  >3x  70  106  (34)  (33)  
% Total Revenue  3.6%  1.0%  +3pp  +3pp  0.6%  1.0%  -  -  
Operating profit  6,959  2,663  >2x  >2x  1,954  1,245  57  69  
Operating Margin  20.6%  8.0%  +13pp  +14pp  17.0%  11.3%  +6pp  +7pp  
Net finance expense  (945) (936) 1  1  (291) (324) (9)  (6)  
Joint ventures and associates  (12) (4) >2x  >2x  (11) 1  n/m  n/m  
Profit before tax  6,002  1,723  >3x  >3x  1,652  922  79  91  
Taxation  (1,000) 668  n/m  n/m  (274) 720  n/m  n/m  
Tax rate  17%  -39%    17%  -78%    
Profit after tax  5,002  2,391  >2x  >2x  1,378  1,642  (16)  (6)  
Earnings per share  $3.22  $1.54  >2x  >2x  $0.89  $1.06  (16)  (6)  
 
Table 12: Reconciliation of Reported Profit before tax to EBITDA 
 
 
55  Other Operating Income.

===== SIDA 19 =====

19 
  9M 2023  9M 2022  % Change Q3 2023  Q3 2022  % Change 
 
  $m  $m  Actual  CER  $m  $m  Actual  CER  
Reported Profit before tax   6,002   1,723   >3x  >3x  1,652   922   79   91   
Net finance expense   945  936  1  1  291  324  (9)  (6)  
Joint ventures and associates   12  4  >2x  >2x  11  (1)  n/m  n/m  
Depreciation, amortisation and 
impairment  
 
4,060  4,000  2  3  1,282  1,334  (4) (4)  
EBITDA   11,019   6,663   65   77   3, 236   2,579   25   32   
 
EBITDA for the comparative 9M 2022 was negatively impacted by $3,175m unwind of inventory fair value uplift 
recognised on the acquisition of Alexion. EBITDA fo r the comparative Q3 2022 was negatively impacted b y 
$857m unwind of inventory fair value uplift recogni sed on the acquisition of Alexion. This unwind had a $78m 
negative impact on 9M 2023 and a $23m negative impa ct on Q3 2023. It will continue to be minimal and w ill 
unwind fully over the next quarter. 
 
Table 13: Reconciliation of Reported to Core financial measures: 9M 2023 
 
9M 2023 
 
Reported  Restructuring  
Intangible Asset 
Amortisation & 
Impairments  
Acquisition  
of Alexion  Other 56  Core  Core 
% Change 
 
  $m   $m   $m   $m  $m  $m  Actual  CER  
Gross profit  27,827  133  24  82  (4) 28,062  4  8  
Product Sales 
Gross Margin 
 81.6%      82.4%  +1pp  +2pp  
Distribution 
expense 
 (394) -  -  -  -  (394) 4  6  
R&D expense  (7,862) 117  386  5  1  (7,353) 5  7  
SG&A expense  (13,845)  163  2,863  7  1,107  (9,705) 5  8  
Total operating 
expense 
 (22,101)  280  3,249  12  1,108  (17,452)  5  7  
Other operating 
income & expense 
 1,233  (61) -  -  -  1,172  >3x  >3x  
Operating profit  6,959  352  3,273  94  1,104  11,782  10  16  
Operating Margin  20.6%          34.9%  +2pp  +3pp  
Net finance 
expense 
 (945) -  -  -  220  (725) (1)  (2)  
Taxation  (1,000) (81) (617) (22) (329) (2,049) 12  19  
EPS  $3.22  $0.17  $1.72  $0.05  $0.64  $5.80  10  17  
 
Table 14: Reconciliation of Reported to Core financial measures: Q3 2023 
 
Q3 2023 
 
Reported  Restructuring  
Intangible Asset 
Amortisation & 
Impairments  
Acquisition  
of Alexion  Other 57  Core  Core 
% Change 
 
  $m   $m   $m   $m  $m  $m  Actual  CER  
Gross profit  9,397  15  8  25  (1) 9,444  6  7  
Product Sales 
Gross Margin 
 81.0%      81.4%  +1pp  +1pp  
Distribution 
expense 
 (129) -  -  -  -  (129) 3  2  
R&D expense  (2,584) 48  49  2  -  (2,485) 5  5  
 
56  Other adjustments include fair-value adjustments r elating to contingent consideration on business com binations and other acquisition-
related liabilities, discount unwind on acquisition-related liabilities (see Note 4) and provision movements related to certain legal matters, 
including a $510m charge to provisions relating to a legal settlement with BMS and Ono and a $425m charge to provisions relating to a 
multidistrict litigation proceeding legal settlement in 9M 2023 (see Note 6).  
57  Other adjustments include fair-value adjustments r elating to contingent consideration on business com binations and other acquisition-
related liabilities, discount unwind on acquisition-related liabilities (see Note 4) and provision movements related to certain legal matters, 
including a $425m charge to provisions relating to a multidistrict litigation proceeding legal settlement in Q3 2023 (see Note 6).

===== SIDA 20 =====

20 
SG&A expense  (4,800) 61  957  3  424  (3,355) 6  7  
Total operating 
expense 
 (7,513) 109  1,006  5  424  (5,969) 6  6  
Other operating 
income & expense 
 70  -  -  -  -  70  (35)  (34)  
Operating profit  1,954  124  1,014  30  423  3,545  4  9  
Operating Margin  17.0%          30.8%  -  +1pp  
Net finance 
expense 
 (291) -  -  -  68  (223) (12)  (7)  
Taxation  (274) (29) (189) (7) (125) (624) 8  13  
EPS  $0.89  $0.06  $0.53  $0.01  $0.24  $1.73  4  9  
 
Profit and Loss drivers 
 
Gross profit  
 
‒ The calculation of Reported and Core Product Sales  Gross Margin excludes the impact of Alliance Revenue 
and Collaboration Revenue. The change in Product Sa les Gross Margin (Reported and Core) in the nine 
months was impacted by: 
 
‒ Positive effects from product mix. The increased c ontribution from Rare Disease and Oncology medicines 
had a positive impact on the Product Sales Gross Margin. Vaxzevria sales , which are dilutive to Product 
Sales Gross Margin, declined substantially  
 
‒ Dilutive effects from product mix. The rising cont ribution of Product Sales with profit sharing arrangements 
(Lynparza, Enhertu  and Tezspire)  has a negative impact on Product Sales Gross Margi n because 
AstraZeneca records product revenues in certain markets but pays away a share of the gross profit to its 
collaboration partners  
 
‒ Dilutive effects from geographic mix. Emerging Mar kets, where Product Sales Gross Margin tends to be 
below the Company average, grew as a proportion of Total Revenue excluding COVID-19 medicines 
 
‒ Variations in Product Sales Gross Margin performan ce between periods can continue to be expected due to 
product seasonality, foreign exchange fluctuations and other effects.  
 
R&D expense 
 
‒ The change in R&D expense (Reported and Core) in t he period was impacted by: 
 
‒ Recent positive data read-outs for several high pr iority medicines that have ungated late-stage trials 
 
‒ Investment in platforms, new technology and capabi lities to enhance R&D productivity 
 
‒ Reported R&D expense was also impacted by intangib le asset impairments 
 
SG&A expense 
 
‒ The change in SG&A expense (Reported and Core) in the period was driven primarily by market 
development activities for launches   
 
‒ Reported SG&A expense was also impacted by amortis ation of intangible assets related to the Alexion 
acquisition and other acquisitions and collaborations 
 
‒ Reported SG&A expense was also impacted by a $510m  charge to provisions relating to a legal settlement 
in Q2 2023 with Bristol-Myers Squibb and Ono Pharma ceutical, and a $425m charge to provisions in Q3 
2023 for product liability litigations related to Nexium  and Prilosec . The prior nine month period was impacted 
by a $775m legal settlement with Chugai Pharmaceutical Co. Ltd 
 
Other operating income and expense 
 
‒ Reported and Core Other operating income and expen se in the period included a $712m gain resulting from 
an update to the contractual relationships for Beyfortus  (nirsevimab), a $241m gain on the disposal of the 
US rights to Pulmicort  Flexhaler , and other disposal proceeds on the sale of tangib le assets, and royalties 
on certain medicines

===== SIDA 21 =====

21 
‒ In the third quarter Reported and Core Other opera ting income decreased by $36m and $37m respectively, 
principally due to the discontinuation of brazikuma b development. Prior to this, AstraZeneca received 
quarterly development contributions for brazikumab development from AbbVie, which were recognised as 
Other operating income 
 
Net finance expense 
 
‒ Reported Net finance expense was impacted by the d iscount unwind on acquisition-related liabilities. Core 
Net finance expense reduced by 1% (2% at CER) with higher interest received on cash and short-term 
investments, broadly offset by higher rates on floating debt and bond issuances 
 
Taxation 
 
‒ The effective Reported Tax rate for the nine month s to 30 September 2023 was 17% (9M 2022: (39%)) and 
the effective Core Tax rate was 19% (9M 2022: 18%).  The Q3 2022 effective Reported Tax rate was lower 
as it included a one-time favourable adjustment of $883m relating to deferred taxes arising from an in ternal 
reorganisation to integrate the Alexion business 
 
‒ The cash tax paid for the nine months to 30 Septem ber 2023 was $1,710m (9M 2022: $1,335m), 
representing 28% of Reported Profit before tax (9M 2022: 77%) 
 
‒ On 20 June 2023, Finance (No.2) Act 2023 was subst antively enacted in the UK, introducing a global 
minimum effective tax rate of 15%. The legislation implements a domestic top-up tax and a multinational top-
up tax, effective for accounting periods starting o n or after 31 December 2023. The Company is current ly 
assessing the impact of these rules upon its financ ial statements.  The Company has applied the except ion 
under the IAS 12 ‘Income Taxes' amendment for recog nising and disclosing information about deferred ta x 
assets and liabilities related to top-up income taxes  
 
Table 15: Cash Flow summary 
 
  9M 2023  9M 2022  Change  
  $m  $m  $m  
Reported Operating profit   6,959  2,663  4,296  
Depreciation, amortisation and impairment   4,060  4,000  60  
Decrease in working capital and short-term provisions   150  3,458  (3,308) 
Gains on disposal of intangible assets   (247) (88) (159) 
Fair value movements on contingent consideration arising from 
business combinations  
 202  293  (91)  
Non-cash and other movements   (623) (973) 350  
Interest paid   (826) (608) (218) 
Taxation paid   (1,710) (1,335) (375) 
Net cash inflow from operating activities   7,965   7,410   555   
Net cash inflow before financing activities   4,978   4,699   279   
Net cash outflow from financing activities   (6,276 ) (6,465 ) 189   
 
In 9M 2022, the Reported Operating profit of $2,663 m included a negative impact of $3,175m relating to  the 
unwind of the inventory fair value uplift recognise d on the acquisition of Alexion. This was offset by  a 
corresponding item (positive impact of $3,175m) in Decrease in working capital and short-term provisio ns. 
Overall, the unwind of the fair value uplift had no impact on Net cash inflow from operating activities. This unwind 
had $78m negative impact on 9M 2023 Reported Operat ing profit and offsetting positive impact on Workin g 
capital movements, and will continue to be minimal in the next quarter. As a result of the update to t he 
contractual relationships between AstraZeneca, Sobi  and Sanofi relating to the future sales of Beyfortus  
(nirsevimab) in the US, a gain of $712m has been re corded in non-cash and other movements, with no ove rall 
net impact on the Net cash inflow from operating activities. 
 
Included within Net cash inflow before financing ac tivities is a movement in the profit-participation liability of 
$190m, including a cash receipt from Sobi in Q1 202 3 after achievement of a regulatory milestone. The 
associated cash flow is presented within investing activities. 
 
The decrease in Net cash outflow from financing activities of $189m is primarily driven by the Issue of loans and 
borrowings of $3,816m, offset by the increase in Repayment of loans and borrowings of $3,394m.

===== SIDA 22 =====

22 
 
Capital expenditure 
 
Capital expenditure amounted to $836m in the nine months to 30 September 2023 (9M 2022: $719m). 
 
Table 16: Net debt summary 
  At 30  
 Sep 2023  
At 31  
Dec 2022  
At 30  
Sep 2022  
  $m  $m  $m  
Cash and cash equivalents  4,871  6,166  4,458  
Other investments  244  239  440  
Cash and investments  5,115  6,405  4,898  
Overdrafts and short-term borrowings  (515) (350)  (743) 
Lease liabilities  (979) (953)  (878) 
Current instalments of loans  (4,857) (4,964)  (4,665) 
Non-current instalments of loans  (22,225)  (22,965)  (23,013)  
Interest-bearing loans and borrowings (Gross debt)  (28,576)  (29,232)  (29,299) 
Net derivatives  90  (96)  (141) 
Net debt  (23,371) (22,923)  (24,542) 
 
 
Net debt increased by $448m in the nine months to 30 September 2023 to $23,371m. Details of the committed 
undrawn bank facilities are disclosed within the go ing concern section of Note 1. Details of the Compa ny's 
solicited credit ratings and further details on Net Debt are disclosed in Note 3. 
 
Capital allocation 
 
The Board's aim is to continue to strike a balance between the interests of the business, financial creditors and 
the Company's shareholders. The Company's capital allocation priorities include: investing in the business and 
pipeline; maintaining a strong, investment-grade credit rating; potential value-enhancing business development 
opportunities; and supporting the progressive dividend policy.  
 
In approving the declaration of dividends, the Board considers both the liquidity of the company and the level of 
reserves legally available for distribution. Divide nds are paid to shareholders from AstraZeneca PLC, a Group 
holding company with no direct operations. The ability of AstraZeneca PLC to make shareholder distributions is 
dependent on the creation of profits for distributi on and the receipt of funds from subsidiary compani es. The 
consolidated Group reserves set out in the Condensed consolidated statement of financial position do not reflect 
the profit available for distribution to the shareholders of AstraZeneca PLC. 
 
Summarised financial information for guarantee of securities of subsidiaries 
 
AstraZeneca Finance LLC ("AstraZeneca Finance”) is the issuer of 0.700% Notes due 2024, 1.200% Notes due 
2026, 4.875% Notes due 2028, 1.750% Notes due 2028, 4.900% Notes due 2030, 2.250% Notes due 2031 and 
4.875% Notes due 2033 (the "AstraZeneca Finance Not es”). Each series of AstraZeneca Finance Notes has 
been fully and unconditionally guaranteed by AstraZ eneca PLC. AstraZeneca Finance is 100% owned by 
AstraZeneca PLC and each of the guarantees by Astra Zeneca PLC is full and unconditional and joint and 
several. 
 
The AstraZeneca Finance Notes are senior unsecured obligations of AstraZeneca Finance and rank equally  
with all of AstraZeneca Finance's existing and future senior unsecured and unsubordinated indebtedness . The 
guarantee by AstraZeneca PLC of the AstraZeneca Fin ance Notes is the senior unsecured obligation of 
AstraZeneca PLC and ranks equally with all of Astra Zeneca PLC's existing and future senior unsecured a nd 
unsubordinated indebtedness. Each guarantee by AstraZeneca PLC is effectively subordinated to any secured 
indebtedness of AstraZeneca PLC to the extent of th e value of the assets securing such indebtedness. T he 
AstraZeneca Finance Notes are structurally subordinated to indebtedness and other liabilities of the subsidiaries 
of AstraZeneca PLC, none of which guarantee the AstraZeneca Finance Notes.  
 
AstraZeneca PLC manages substantially all of its operations through divisions, branches and/or investments in 
subsidiaries and affiliates. Accordingly, the abili ty of AstraZeneca PLC to service its debt and guara ntee 
obligations is also dependent upon the earnings of its subsidiaries, affiliates, branches and division s, whether 
by dividends, distributions, loans or otherwise.

===== SIDA 23 =====

23 
Please refer to the consolidated financial statemen ts of AstraZeneca PLC in our Annual Report on Form 20-F 
and reports on Form 6-K with our quarterly financia l results as filed or furnished with the SEC 58  for further 
financial information regarding AstraZeneca PLC and  its consolidated subsidiaries. For further details , terms 
and conditions of the AstraZeneca Finance Notes ple ase refer to AstraZeneca PLC's reports on Form 6-K 
furnished to the SEC on 3 March 2023 and 28 May 2021. 
 
Pursuant to Rule 13-01 and Rule 3-10 of Regulation S-X under the Securities Act of 1933, as amended (t he 
"Securities Act”), we present below the summary fin ancial information for AstraZeneca PLC, as Guaranto r, 
excluding its consolidated subsidiaries, and AstraZ eneca Finance, as the issuer, excluding its consoli dated 
subsidiaries. The following summary financial infor mation of AstraZeneca PLC and AstraZeneca Finance i s 
presented on a combined basis and transactions betw een the combining entities have been eliminated. 
Financial information for non-guarantor entities ha s been excluded. Intercompany balances and transact ions 
between the obligor group and the non-obligor subsidiaries are presented on separate lines. 
 
Table 17: Obligor group summarised Statement of comprehensive income 
 
  9M 2023  9M 2022  
  $m  $m  
Total Revenue  -  -  
Gross profit  -  -  
Operating loss  (2)  (3) 
Loss for the period  (695) (404) 
Transactions with subsidiaries that are not issuers or guarantors  9,758  502  
 
Table 18: Obligor group summarised Statement of financial position  
 
  At 30 Sep 2023  At 30 Sep 2022  
  $m  $m  
Current assets  6  5  
Non-current assets  -  -  
Current liabilities  (4,760) (3,067) 
Non-current liabilities  (22,077)  (22,556)  
Amounts due from subsidiaries that are not issuers or guarantors   12,921  7,349  
Amounts due to subsidiaries that are not issuers or guarantors   (295) (301) 
 
Foreign exchange 
 
The Company's transactional currency exposures on working-capital balances, which typically extend for up to 
three months, are hedged where practicable using fo rward foreign exchange contracts against the indivi dual 
companies' reporting currency. Foreign exchange gai ns and losses on forward contracts for transactiona l 
hedging are taken to profit or loss. In addition, t he Company's external dividend payments, paid princ ipally in 
pounds sterling and Swedish krona, are fully hedged from announcement to payment date. 
 
Table 19: Currency sensitivities 
 
The Company provides the following currency-sensitivity information: 
 
  
 
 Average  
rates vs. USD  
Annual impact ($m) of 
5% strengthening 
(FY2023 average rate 
vs. FY 2022 average)  59  
 
 
58  Securities Exchange Commission. 
59  Based on best prevailing assumptions around currency profiles.

===== SIDA 24 =====

24 
Currency Primary Relevance   FY     
2022 60  
YTD     
2023 61  
Change  
 (%)  
Sep 
2023 62  
Change 63  
 (%)  
 Total 
Revenue  
Core 
Operating 
Profit  
EUR Total Revenue  0.95  0.92  3 0.94  1  323   159  
CNY Total Revenue  6.74  7.04  (4)  7.30  (8)   309   174  
JPY Total Revenue  131.59  138.18  (5)  147.71  (11)   181   122  
Other 64          385   202  
GBP Operating expense  0.81  0.80  1 0.81  0  46   (92)  
SEK Operating expense  10.12  10.59  (4)  11.08  (9)   7  (55)  
 
Sustainability 
 
Since the last quarterly report, AstraZeneca: 
 
Access to healthcare 
 
‒ Hosted the first dedicated side-event on Chronic K idney Disease (CKD) "How improving kidney health ca n 
transform health systems for all” during the 78th United Nations General Assembly (UNGA) meeting in New 
York, with public, private and patient voices repre sented. During UNGA, the Company also engaged with 
the cancer community on access, services within uni versal health coverage (UHC) and the need for 
investment in cancer and non-communicable diseases (NCDs) 
 
‒ Continued to make a high-level contribution to the  work of the Partnership for Health System Sustaina bility 
and Resilience (PHSSR), which provides a valuable p latform for dialogue with policymakers, the Company  
and other stakeholders. In Canada, a workshop with participation from the Minister of Health of Quebec fed 
into the discussions on transformation of Quebec's health system. In Japan, AstraZeneca's Chair Michel  
Demaré participated in a PHSSR roundtable co-hosted  by the British Embassy, which focused on health 
equity and digital healthcare. PHSSR also engaged a t leading global and regional healthcare events, 
including the European Health Forum Gastein, the Global Congress on Population, Health and Development, 
ICHOM 2023 and the World Health Summit in Berlin 
 
‒ Ruud Dobber, EVP BioPharmaceuticals Business Unit,  delivered the opening keynote address at the 
POLITICO EU Healthcare Summit in Brussels where he called for bold action and collaboration across the  
healthcare ecosystem to support early diagnosis and  treatment. He highlighted the need for regulatory 
frameworks that accelerate access to medical innovation, as well as the urgency to combat the effects of the 
climate crisis on health 
 
‒ Marked World Heart Day and the ninth anniversary o f Healthy Heart Africa (HHA)'s launch, by convening  
African health stakeholders to take stock of the programme's achievements and share insights on the critical 
role of public-private partnerships in supporting p rimary healthcare. Speakers included representative s of 
Ministries of Health from nine countries and HHA implementing partners, with more than 70 attendees. HHA 
has trained more than 11,000 healthcare workers and conducted over 43 million blood pressure screenings, 
identifying 8.6 million with elevated blood pressur e since launch, moving closer to the programme ambi tion 
of 10 million by 2025, and achieving one million sc reenings per month since February 2023 (data as at end 
of September 2023) 
 
‒ Young Health Programme is now active in 40 countri es, with new programmes launched in Costa Rica and 
Taiwan. Through the Young Health Programme Impact Fellowship, the Company supported a delegation of 
17 young health leaders from 13 countries to attend  One Young World 2023 in Belfast. Three of these 
changemakers joined AstraZeneca leadership in on-st age appearances, discussing their impact on NCD 
prevention for young people in their communities. A straZeneca and Plan International UK were awarded 
‘Highly Commended' at the Corporate Engagement Awards for Best Educational Programme 
 
Environmental protection  
 
 
60  Based on average daily spot rates 1 Jan 2022 to 31 Dec 2022. 
61  Based on average daily spot rates 1 Jan 2023 to 30 Sep 2023. 
62  Based on average daily spot rates 1 Sep 2023 to 30 Sep 2023. 
63  Change vs. the average spot rate for the previous year 
64  Other currencies include AUD, BRL, CAD, KRW and RUB.

===== SIDA 25 =====

25 
‒ Entered into an agreement in Sweden with Statkraft , Europe's largest renewable energy producer, on wi nd 
power deliveries that will increase the supply of r enewable electricity in Sweden. The agreement is ba sed 
on the commissioning of new wind farms. Under the a greement, AstraZeneca commits to purchasing 200 
gigawatt-hours per year for 10 years, equivalent to  two terawatt-hours. This corresponds to approximat ely 
80 percent of total electricity needs at both the C ompany's Gothenburg site and at Södertälje, the lar gest 
manufacturing centre and one of the world's largest drug manufacturing centres 
 
‒ Agreed a 15-year partnership with Future Biogas to  establish the first unsubsidised industrial-scale supply 
of biomethane in the UK. This biomethane will support the transition away from fossil fuels at Company sites 
in Macclesfield, Cambridge, Luton and Speke. A new biomethane plant will add renewable energy capacity  
to existing UK infrastructure and supply more than 100 gigawatt hours of biomethane, equivalent to the heat 
needs of more than 8,000 homes. Using crops grown l ocally as part of diverse crop rotations, the plant  will 
also contribute to the development of a circular ec onomy, supporting UK farms with sustainable land 
management practices 
 
‒ In China, CEO Pascal Soriot and EVP and China Pres ident Leon Wang witnessed the launch of the 
Sustainable Markets Initiative (SMI) China Council Health Working Group. Inspired by the SMI Health 
Systems Task Force, members of this new partnership  will collaborate to accelerate the delivery of a n et 
zero health system, for domestic and global impact.  AstraZeneca China will co-chair this Working Group , 
which comprises China-based organisations and Chinese affiliates of global pharmaceutical companies  
 
‒ In the U.S., advocated for climate action and sust ainable healthcare reform during Climate Week NYC b y 
convening high-level representatives from the US go vernment, WHO, civil society and philanthropy at a 
plenary event with Climate Group on ”Addressing the climate-health-equity nexus: The path to a sustainable 
future”. The Company also discussed accelerating health sector decarbonisation at the Forbes Sustainability 
Leaders Summit in a session on "How the healthcare industry is responding to climate change" alongside  
US National Academy of Medicine President Dr. Victo r J. Dzau. Furthermore, the Company participated in  
an event on water stewardship 
 
‒ Contributed to a joint report on Advancing water s tewardship through supplier collaboration in partne rship 
with the World Wide Fund for Nature 
 
‒ Ranked in first position for climate action in a n ew STAT Report "Climate rankings: How top drug companies 
measure up in combating climate change”, which noted that "Companies like AstraZeneca are the exception 
in an industry that, as a whole, could be doing muc h more to measure and report its climate impacts, 
according to organizations that pool data on this topic” 
 
‒ Received the EcoVadis Gold Medal for 2023, improvi ng on the 2022 Silver rating. AstraZeneca was score d 
in four areas: Environment, Ethics, Labor and Human  Rights, and Sustainable Procurement, and received 
an Advanced rating in the Environment and Human Rights categories 
 
‒ Recognised with two awards from My Green Lab and t he International Institute for Sustainable Laboratories' 
in the 2023 Freezer Challenge: the Top Organization  Award and the Small Size Lab Award for our site in  
Gothenburg, Sweden 
 
Ethics and transparency 
  
‒ Received three supplier diversity awards from the Diversity for Science Alliance including 2023 Company of 
the year 
 
‒ Launched Global Ethics training ahead of Global Et hics Day in October, an annual reminder to employee s 
of the Company's commitment to high ethical standards in all areas of AstraZeneca's business, marking the 
day with local and virtual events and an #EmpoweringEthics employee social campaign 
 
‒ Held an internal Power of Diversity panel discussi on with members of the Company's Global Inclusion &  
Diversity (I&D) Council on the topic of putting an I&D lens over our AZ Values. This focused on buildi ng a 
sense of belonging through allyship, mutual support  and the sharing of diverse perspectives. Supportin g 
materials were made available through employee communication channels 
 
Research and development 
 
This section covers R&D events and milestones that have occurred since the prior results announcement on 
28 July 2023, up to and including events on 8 November 2023.

===== SIDA 26 =====

26 
A comprehensive view of AstraZeneca's pipeline of medicines in human trials can be found in the latest Clinical 
Trials Appendix, available on www.astrazeneca.com/i nvestor-relations. The Clinical Trials Appendix inc ludes 
tables with details of the ongoing clinical trials for AstraZeneca medicines and new molecular entitie s in the 
pipeline.  
 
Oncology 
 
AstraZeneca presented new data across its diverse p ortfolio of cancer medicines at two major medical 
congresses during the quarter: the 2023 World Confe rence on Lung Cancer (WCLC) in September and the 
2023 European Society of Medical Oncology (ESMO) in October. At WCLC, AstraZeneca presented more than 
40 abstracts featuring eight approved and potential new medicines, including nine oral presentations and a late-
breaking plenary Presidential Symposium presentatio n of results from the FLAURA2 Phase III trial of Tagrisso 
plus chemotherapy in 1st-line EGFR m NSCLC. At ESMO, AstraZeneca presented nearly 100 abstracts 
featuring 19 approved and potential new medicines i ncluding 26 oral presentations and two late-breakin g 
Presidential Symposia of the TROPION-Lung01 and TROPION-Breast 01 Phase III trials of monotherapy Dato-
DXd versus conventional chemotherapy in lung and breast cancers. 
 
Tagrisso  
 
Event   Commentary 
Breakthrough 
Designation 
US 
 Tagrisso  in combination with chemotherapy for the treatment of adult patients with 
locally advanced or metastatic EGFRm lung cancer. (FLAURA2, August 2023) 
Presentation: 
WCLC 
FLAURA2 
 Interim analysis of the Phase III FLAURA2 trial, presented at WCLC, demonstrated 
Tagrisso  plus chemotherapy extended median PFS 65  by nearly nine months and 
reduced the risk of disease progression by 38% in EGFRm advanced lung cancer 
vs. Tagrisso monotherapy. (September 2023)  
Priority Review US  Tagrisso  in combination with chemotherapy for the treatment of adult patients with 
locally advanced or metastatic EGFRm lung cancer. (FLAURA2, October 2023) 
Presentation: 
ESMO 
FLAURA2   
CNS analysis 
 Prespecified exploratory analysis of the Phase III FLAURA2 trial, presented at 
ESMO, showed  Tagrisso  plus chemotherapy demonstrated a 42% improvement 
in CNS 66  PFS vs. Tagrisso  monotherapy in patients with EGFRm advanced lung 
cancer and brain metastases at baseline, representing 40% of patients in the trial, 
as assessed by blinded independent central review. (October 2023) 
 
Imfinzi and  Imjudo  
 
Event   Commentary 
Positive Opinion  
 
EU 
 
 The Committee for Medicinal Products for Human Use (CHMP) issued a positive 
opinion for Type II Extension of Indication Variation for Imfinzi  as monotherapy for 
the first line treatment of adults with advanced or unresectable HCC. (HIIMALAYA, 
July 2023) 
Presentation: 
ESMO 
MATTERHORN 
  Interim analysis of the Phase III MATTERHORN III tria l, presented at ESMO, 
showed that Imfinzi  in combination with standard-of-care FLOT 67  neoadjuvant 
chemotherapy demonstrated a statistically significant and clinically meaningful 12% 
improvement in the key secondary endpoint of pCR 68  vs. neoadjuvant 
chemotherapy alone for patients with resectable, early-stage and locally gastric and 
GEJ 69  cancers. (October 2023) 
Phase III data 
readout 
EMERALD-1 
 Positive high-level results from the EMERALD-1 Phase III trial showed Imfinzi  in 
combination with TACE 70  and bevacizumab demonstrated a statistically significant 
and clinically meaningful improvement in the primary endpoint of PFS versus TACE 
 
65  Progression free survival. 
66  Central nervous system. 
67  Fluorouracil, oxaliplatin and docetaxel . 
68  Pathologic complete response. 
69  Gastro oesophageal junction. 
70  Transarterial chemoembolisation.

===== SIDA 27 =====

27 
alone in patients with HCC eligible for embolisation. The trial continues to follow the 
secondary endpoint of OS 71 . (November 2023) 
 
 
Lynparza 
 
Event   Commentary 
Approval  Japan  Lynparza  in combination with abiraterone and prednisolone f or the treatment of 
adult patients with BRCAm mCRPC. (August 2023) 
Label restriction US  Restriction of the Lynparza  indication for the maintenance treatment of adult 
patients with recurrent epithelial ovarian, fallopi an tube, or primary peritoneal 
cancer who are in a complete or partial response to platinum-based chemotherapy 
to the BRCAm (germline or somatic) patient population only. (September 2023) 
Presentation: 
ESMO 
DUO-E 
(Lynparza and 
Imfinzi ) 
 Primary analysis of the Phase III DUO-E Phase III tr ial, presented at ESMO, 
showed that treatment with Imfinzi  plus chemotherapy followed by either Imfinzi  
monotherapy or Imfinzi  plus Lynparza demonstrated a reduction in the risk of 
disease progression or death, by 45% and 29%, respe ctively, vs. chemotherapy 
alone in patients with advanced or recurrent endometrial cancer. (October 2023) 
 
Enhertu 
 
Event   Commentary 
Approval  Japan  For the treatment of adult patients with unresectable advanced or recurrent NSCLC 
with HER2 (ERBB2) mutations that has progressed afte r chemotherapy. 
(DESTINY-Lung02, August 2023) 
Breakthrough 
Designation 
US 
 
 For the treatment of adult patients with unresectable or metastatic HER2-positive 
(IHC 72  3+) solid tumours that have progressed following p rior treatment and who 
have no alternative treatment options. (DESTINY-PanTumor02, August 2023) 
   For the treatment of patients with HER2-positive (IH C 3+) metastatic colorectal 
cancer who have received two or more prior regimens . (DESTINY-CRC01, 
DESTINY-CRC02, August 2023) 
Presentation: 
WCLC 
DESTINY-
Lung02 
 Results from the primary analysis of the DESTINY-Lung02 Phase II trial, presented 
at WCLC, showed Enhertu  provided a median PFS of 9.9 months at a dose of 
5.4mg/kg, and 15.4 months at a dose of 6.4mg/kg, with a favourable safety profile 
that confirm 5.4mg/kg is the optimal dose in this tumour type. (September 2023) 
 
 
Approval  EU  As monotherapy for the treatment of adult patients with advanced NSCLC whose 
tumours have an activating HER2 (ERBB2 73 ) mutation and who require systemic 
therapy following platinum-based chemotherapy with or without immunotherapy. 
(DESTINY-Lung02, October 2023) 
 
Presentation: 
ESMO 
DESTINY-
PanTumor02 
 Primary analysis of the Phase II DESTINY-PanTumor02 trial, presented at ESMO, 
showed that treatment with Enhertu  resulted in confirmed ORR 74  of 37.1%, a 
median PFS of 6.9 months and median OS of 13.4 mont hs in previously treated 
patients across multiple HER2-expressing advanced solid tumours. (October 2023)  
 
Calquence 
 
Event   Commentary 
Approval  China 
 
 For the treatment of adult patients with CLL or SLL 75  who have received at least 
one prior therapy. (ASCEND, September 2023) 
 
 
71  Overall survival. 
72  Immunohistochemistry. 
73  v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2. 
74  Overall response rate. 
75  Small lymphocytic lymphoma.

===== SIDA 28 =====

28 
datopotamab deruxtecan (Dato-Dxd) 
 
Event   Commentary 
Presentation: 
WCLC 
TROPION-
Lung04 
 Results from a planned interim analysis of the Phas e Ib TROPION-Lung04 trial, 
presented at WCLC, showed that Dato-DXd in combinatio n with Imfinzi , with or 
without carboplatin demonstrated objective response rates of 77% and 50% and 
disease control rates of 92% and 93% respectively, with no new safety signals in 
patients with previously untreated advanced or meta static NSCLC without 
actionable genomic alterations. (September 2023) 
Presentation: 
ESMO 
BEGONIA 
 Updated results from the Phase Ib/II BEGONIA trial, presented at ESMO, showed 
Dato-DXd plus Imfinzi  demonstrated a confirmed objective response rate of 79% 
and a median PFS of 13.8 months in patients with previously untreated advanced 
or metastatic triple-negative breast cancer. (October 2023) 
Presentation: 
ESMO 
TROPION-
Lung01 
 Primary analysis for the Phase III TROPION-Lung01 tr ial, presented at ESMO, 
showed that Dato-DXd reduced the risk of disease progression or death by 25% in 
the overall population and by 37% in non-squamous t umours vs. docetaxel in 
patients with previously treated NSCLC. (October 2023) 
Presentation: 
ESMO 
TROPION-
Breast01 
 Primary analysis for the Phase III TROPION-Breast01 trial, presented at ESMO, 
showed that Dato-DXd reduced the risk of disease progression or death by 37%, 
providing a two-month median PFS benefit, and was wel l tolerated in the post-
endocrine therapy setting vs. investigator's choice of chemotherapy in patients with 
inoperable or metastatic HR-positive, HER2-low or HER2-negative breast cancer 
previously treated with endocrine-based therapy and at least one systemic therapy. 
(October 2023) 
 
Other oncology pipeline 
 
Event   Commentary 
Trial update MONETTE  Phase II trial of ceralasertib + Imfinzi  in unresectable or advanced melanoma and 
resistance to PD-(L)1 inhibition stopped enrolment following a pre-specified futility 
(efficacy) assessment. There were no concerning safety signals identified at this 
interim analysis or during the two prior data review meetings.  
Presentation: 
ASCO Virtual 
Plenary 
NCT04805307  Interim analysis for the Phase I trial (NCT04805307)  of CMG901 (Claudin 18.2 
ADC 76 ) demonstrated promising clinical efficacy in patients with heavily pre-treated 
CLDN18.2-positive gastric/GEJ cancer, with a manage able safety profile. 
(November 2023) 
 
BioPharmaceuticals - CVRM 
 
AstraZeneca presented 19 abstracts, including 10 or al presentations and five late-breaking presentatio ns, at 
the European Society of Cardiology (ESC) Congress in August, including data highlighting the opportunities for 
improved management in heart failure, and AstraZeneca's leadership across the interconnectedness of chronic 
diseases. At the American Society of Nephrology's ( ASN) Kidney Week in November, AstraZeneca presented  
53 abstracts showcasing the strength of its portfol io, including new ZORA and REVOLUTIONIZE real-world  
evidence data for Lokelma  and compelling next-wave pipeline innovation with results from the ZENITH-CKD 
Phase IIb trial for zibotentan/dapagliflozin. 
 
Farxiga 
 
Event   Commentary 
Approval  
 
China 
 
 Approved in China to reduce the risk of cardiovascul ar death, hospitalisation for 
HF 77  or urgent HF visits in adults with symptomatic chronic HF. (June 2023) 
Data T2NOW  Positive data from the Phase III T2NOW trial, demonstrating a significant reduction 
in A1C in patients aged 10-17 years compared to pat ients receiving placebo. 
(October 2023) 
Data DAPA-MI  Primary endpoint met, non-registrational trial. (August 2023) 
 
76  Antibody drug conjugate. 
77  Heart failure.

===== SIDA 29 =====

29 
 
zibotentan/dapagliflozin  
 
Event   Commentary 
Presentation: 
ASN  
 
ZENITH-CKD  Phase IIb data showed statistically significant and clinically meaningful  
reductions in urinary albumin-to-creatinine ratio ( UACR), used to assess 
albuminuria, at 12 weeks compared with the standard  of care of dapagliflozin 
alone. After 12 weeks of treatment, the UACR differ ence of 
zibotentan/dapagliflozin versus dapagliflozin alone  was -33.7% (90% CI -42.5 
to -23.5; p<0.001) for high-dose (1.5 mg zibotentan  / 10 mg dapagliflozin) and -
27.0% (90% CI -38.4 to -13.6; p=0.002) for low dose  (0.25 mg/10mg). 
(November 2023) 
 
Eplontersen 
 
Event   Commentary 
Orphan Drug 
Designation 
 
EU 
 Orphan drug designation received for the treatment of ATTR 78 . (October 2023) 
 
BioPharmaceuticals - R&I  
  
AstraZeneca presented new data across its inhaled, biologic and early science respiratory portfolio at  the 
European Respiratory Society (ERS) International Congress 2023. The company presented over 90 abstract s, 
including 18 oral presentations, which focused on unmet needs in severe asthma, chronic obstructive pulmonary 
disease and other acute respiratory diseases. Data from Fasenra and Tezspire  advanced clinical remission as 
a treatment target to change the trajectory of severe asthma care.  
 
Fasenra   
 
Event   Commentary 
Phase III data 
readout  
MANDARA    
 Positive high-level results from the MANDARA Phase I II trial for Fasenra 
demonstrated non-inferior rates of remission compared to mepolizumab in patients 
with EGPA who were receiving oral corticosteroids w ith or without stable 
immunosuppressive therapy. MANDARA was the first he ad-to-head trial of 
biologics in EGPA, comparing a single monthly injec tion of Fasenra to three 
injections per month of mepolizumab, the only curre ntly approved treatment. 
(September 2023)  
Presentation: 
ERS  
SHAMAL   
 SHAMAL assessed the ability of Fasenra to permit a progressive reduction from 
high-dose ICS/LABA down to anti-inflammatory reliever whilst maintaining control 
in SEA 79  pts who were well-controlled on Fasenra . Fasenra enabled the majority of 
SEA patients to maintain disease control and remain exacerbation-free despite a 
reduction in background therapy to anti-inflammator y reliever only. (September 
2023)  
Presentation: 
ERS  
MIRACLE   
 The positive MIRACLE Phase III trial demonstrated a reduction in annual asthma 
exacerbation rate of 74% among patients in China wi th uncontrolled SEA vs. 
placebo. A filing for regulatory approval in China has been submitted, with a 
decision expected in H2 2024. (September 2023)  
 
Tezspire   
  
Event   Commentary 
Presentation: 
ERS  
DESTINATION   
 In a post-hoc exploratory analysis of the DESTINATION Phase III trial of patients 
with severe, uncontrolled asthma, a numerically greater proportion of patients who 
received tezepelumab than placebo achieved remissio n during the time periods 
assessed. (September 2023)  
  
 
78  Transthyretin-mediated amyloid cardiomyopathy and transthyretin-mediated amyloid polyneuropathy 
79  Severe eosinophilic asthma.

===== SIDA 30 =====

30 
 
BioPharmaceuticals - V&I  
 
AZD3152 
 
Event   Commentary 
Presentation:  
ID Week 
In-vitro 
neutralisation 
data 
 
 In vitro  neutralisation data presented at ID Week showed th at AZD3152 potently 
neutralises across a broad range of historical and contemporary SARS-CoV-2 
variants, including the newly emerging BA.2.86 vari ant. AZD3152 loses activity 
against XBB variants with the F456L mutation. (October 2023) 
 
The SUPERNOVA Phase III efficacy trial, which is now fully enrolled, will assess 
the potential benefit of AZD3152 in protecting immunocompromised patients in an 
environment with many variants in circulation.  
  
 
FluMist 
 
Event   Commentary 
sBLA 
submission 
 
Self 
administration 
 The FDA has accepted for review a sBLA for the approval of a self- or caregiver-
administered option for FluMist . If approved, FluMist  will be the first flu vaccine 
available to be self-administered by eligible patients or administered by caregivers. 
The sBLA is supported by a usability study which confirmed that individuals over 18 
years of age could self-administer or administer FluMist  to eligible patients 2-49 
years of age when given instructions for use withou t any additional guidance. 
(October 2023) 
 
Rare Disease  
 
Alexion, AstraZeneca Rare Disease presented new real-world and clinical data at the European Committee for 
Treatment and Research in Multiple Sclerosis and Americas Committee for Treatment and Research in Multiple 
Sclerosis (ECTRIMS-ACTRIMS), offering further evide nce to support the established safety and efficacy of 
Soliris  and Ultomiris  in treating NMOSD. 
 
 
Alexion, AstraZeneca Rare Disease presented new cli nical data at the American Society of Nephrology (A SN) 
for Ultomiris  in IgAN 80  as well as real-world data in aHUS. 
 
Alexion, AstraZeneca Rare Disease presented new real-world and clinical data at the American Association of 
Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and Myasthenia Gravis Foundation of 
America Scientific Session (MGFA SS). Data shared across 13 abstracts, reinforcing the safety and efficacy of 
C5 inhibition in treating generalized myasthenia gravis (gMG). 
 
Soliris 
 
Event   Commentary 
Approval  Japan  Paediatric patients with gMG. (August 2023) 
Approval  China  Adults with anti - aquaporin-4 antibody-positive NMOSD. (October 2023) 
 
Ultomiris 
 
Event   Commentary 
CRL US  The US FDA issued a CRL 81  regarding the sBLA 82  for Ultomiris  for the treatment of 
adults with NMOSD. The sBLA included data from the CHAMPION-NMOSD Phase 
III trial, which met the primary endpoint with a saf ety profile consistent with the 
known profile of the medicine.  The CRL requested modifications to enhance the 
Ultomiris  Risk Evaluation and Mitigation Strategy to further  validate patients' 
 
80  Immunoglobulin A neuropathy. 
81  Compete Response Letter. 
82  Supplemental biologics license application.

===== SIDA 31 =====

31 
meningococcal vaccination status or prophylactic administration of antibiotics prior 
to treatment. (September 2023) 
Presentation: 
ASN  
SANCTUARY 
Phase II 
 Ultomiris  demonstrated c linically meaningful efficacy and proof-of-concept as a 
potential treatment for IgAN, based on rapid and su stained proteinuria reduction. 
(November 2023) 
 
vemircopan 
 
Event   Commentary 
Termination  
ACH228 -110 
Phase II 
 Trial discontinued due to lack of efficacy. Followi ng an interim analysis, 
vemircopan's ability to appropriately control intra vascular haemolysis was not 
adequately shown, due to significantly increased rates of breakthrough haemolysis 
and high levels of LDH 83 . No new safety findings were observed, and the saf ety 
profile of vemircopan has been favourable to date. This decision does not impact 
ongoing Phase II trials. (September 2023) 
 
gefurulimab 
 
Event   Commentary 
Orphan Drug 
Designation 
US 
 gefurulimab was granted orphan drug designation by the FDA for the treatment of 
patients with gMG. (September 2023) 
 
ALXN2220 
 
Event   Commentary 
Orphan Drug 
Designation 
US 
 ALXN2220 was granted orphan drug designation by the FDA for the treatment of 
patients with ATTR-CM 84 . (September 2023) 
 
Interim financial statements 
 
Table 20: Condensed consolidated statement of comprehensive income: 9M 2023 
 
For the nine months  ended 30 September  2023  2022  
  $m  $m  
Total Revenue 85   33,787  33,144  
Product Sales  32,466  32,200  
Alliance Revenue   1,004  504  
Collaboration Revenue  317  440  
Cost of sales  (5,960) (9,491) 
Gross profit  27,827  23,653  
Distribution expense  (394) (380) 
Research and development expense  (7,862) (7,137) 
Selling, general and administrative expense  (13,845)  (13,798)  
Other operating income and expense  1,233  325  
Operating profit  6,959  2,663  
Finance income  236  50  
Finance expense  (1,181) (986) 
Share of after tax losses in associates and joint ventures  (12) (4) 
Profit before tax  6,002  1,723  
Taxation  (1,000) 668  
Profit for the period  5,002  2,391  
Other comprehensive income    
Items that will not be reclassified to profit or loss     
Remeasurement of the defined benefit pension liability  (1)  1,283  
 
83  Lactic dehydrogenase. 
84  Transthyretin-mediated amyloid cardiomyopathy. 
85  Effective 1 January 2023, the Group has updated the presentation of Total Revenue. See Note 1 for further details of the presentation of 
Alliance Revenue.

===== SIDA 32 =====

32 
Net gains/(losses) on equity investments measured at fair value through other 
comprehensive income 
 45  (21) 
Fair value movements related to own credit risk on bonds designated as fair value 
through profit or loss 
 5  1  
Tax on items that will not be reclassified to profit or loss  -  (291) 
  49  972  
Items that may be reclassified subsequently to profit or loss     
Foreign exchange arising on consolidation  (201)  (2,493) 
Foreign exchange arising on designated liabilities in net investment hedges  (63) (321) 
Fair value movements on cash flow hedges  62  (214) 
Fair value movements on cash flow hedges transferred to profit and loss  28  250  
Fair value movements on derivatives designated in net investment hedges  47  33  
Costs of hedging  (3) (11) 
Tax on items that may be reclassified subsequently to profit or loss  (7)  95  
  (137)  (2,661) 
Other comprehensive loss, net of tax  (88)  (1,689) 
Total comprehensive income for the period  4,914  702  
Profit attributable to:    
Owners of the Parent  4,995  2,387  
Non-controlling interests  7  4  
  5,002  2,391  
Total comprehensive income attributable to:      
Owners of the Parent  4,907  701  
Non-controlling interests  7  1  
  4,914  702  
Basic earnings per $0.25 Ordinary Share  $3.22  $1.54  
Diluted earnings per $0.25 Ordinary Share  $3.20  $1.53  
Weighted average number of Ordinary Shares in issue (millions)  1,549  1,548  
Diluted weighted average number of Ordinary Shares in issue (millions)  1,560  1,560  
 
Table 21: Condensed consolidated statement of comprehensive income: Q3 2023 
 
For the quarter  ended 30 September  2023  2022  
  $m  $m  
Total Revenue 85   11,492  10,982  
Product Sales  11,018  10,590  
Alliance Revenue   377  214  
Collaboration Revenue  97  178  
Cost of sales  (2,095) (2,982) 
Gross profit  9,397  8,000  
Distribution expense  (129) (126) 
Research and development expense  (2,584) (2,458) 
Selling, general and administrative expense  (4,800) (4,277) 
Other operating income and expense  70  106  
Operating profit  1,954  1,245  
Finance income  101  15  
Finance expense  (392) (339) 
Share of after tax (losses)/profits in associates and joint ventures  (11) 1  
Profit before tax  1,652  922  
Taxation  (274) 720  
Profit for the period  1,378  1,642  
Other comprehensive income    
Items that will not be reclassified to profit or loss    
Remeasurement of the defined benefit pension liability  (8)  252  
Net gains/(losses) on equity investments measured at fair value through other 
comprehensive income 
 93  (9)

===== SIDA 33 =====

33 
Fair value movements related to own credit risk on bonds designated as fair value 
through profit or loss 
 1  (1)  
Tax on items that will not be reclassified to profit or loss  5  (16) 
  91  226  
Items that may be reclassified subsequently to profit or loss     
Foreign exchange arising on consolidation  (306) (1,167) 
Foreign exchange arising on designated liabilities in net investment hedges  38  (126) 
Fair value movements on cash flow hedges  (27)  (76) 
Fair value movements on cash flow hedges transferred to profit and loss  99  119  
Fair value movements on derivatives designated in net investment hedges  7  (1)  
Costs of hedging  (2) 2  
Tax on items that may be reclassified subsequently to profit or loss  (19)  49  
  (210)  (1,200) 
Other comprehensive loss, net of tax  (119) (974) 
Total comprehensive income for the period  1,259  668  
Profit attributable to:    
Owners of the Parent  1,374  1,640  
Non-controlling interests  4  2  
  1,378  1,642  
Total comprehensive income attributable to:      
Owners of the Parent  1,255  667  
Non-controlling interests  4  1  
  1,259  668  
Basic earnings per $0.25 Ordinary Share  $0.89  $1.06  
Diluted earnings per $0.25 Ordinary Share  $0.88  $1.05  
Weighted average number of Ordinary Shares in issue (millions)  1,549  1,548  
Diluted weighted average number of Ordinary Shares in issue (millions)  1,560  1,559  
 
Table 22: Condensed consolidated statement of financial position 
 
  At 30 Sep  
2023  
At 31 Dec  
2022  
At 30 Sep  
2022 
  $m   $m   $m   
Assets     
Non-current assets     
Property, plant and equipment  8,723  8,507  8,352  
Right-of-use assets  977  942  875  
Goodwill  19,939  19,820  19,707  
Intangible assets  37,687  39,307  39,585  
Investments in associates and joint ventures  62  76  53  
Other investments  1,228  1,066  1,049  
Derivative financial instruments  151  74  112  
Other receivables  761  835  792  
Deferred tax assets  4,057  3,263  3,436  
  73,585  73,890  73,961  
Current assets     
Inventories  5,292  4,699  5,078  
Trade and other receivables  11,300  10,521  9,336  
Other investments  244  239  440  
Derivative financial instruments  97  87  105  
Intangible assets  -  -  82  
Income tax receivable  697  731  725  
Cash and cash equivalents  4,871  6,166  4,458  
Assets held for sale   -  150  - 
  22,501  22,593  20,224  
Total assets  96,086  96,483  94,185  
Liabilities

===== SIDA 34 =====

34 
  At 30 Sep  
2023  
At 31 Dec  
2022  
At 30 Sep  
2022 
  $m   $m   $m   
Current liabilities      
Interest-bearing loans and borrowings  (5,372) (5,314)  (5,408) 
Lease liabilities  (235) (228)  (210) 
Trade and other payables  (20,542)  (19,040)  (17,694) 
Derivative financial instruments  (83)  (93)  (68) 
Provisions  (1,193) (722)  (377) 
Income tax payable  (1,163) (896)  (1,093) 
  (28,588) (26,293)  (24,850)  
Non-current liabilities     
Interest-bearing loans and borrowings  (22,225)  (22,965)  (23,013)  
Lease liabilities  (744) (725)  (668) 
Derivative financial instruments  (75) (164)  (290) 
Deferred tax liabilities  (2,752) (2,944)  (3,479) 
Retirement benefit obligations  (1,048) (1,168)  (919) 
Provisions  (1,189) (896)  (930) 
Other payables  (2,244) (4,270)  (4,882) 
  (30,277) (33,132)  (34,181)  
Total liabilities  (58,865) (59,425)  (59,031)  
Net assets  37,221  37,058  35,154  
Equity      
Capital and reserves attributable to equity holders of the 
Parent 
    
Share capital  387  387  387  
Share premium account  35,166  35,155  35,137  
Other reserves  2,078  2,069  2,081  
Retained earnings  (434) (574)  (2,471) 
  37,197  37,037  35,134  
Non-controlling interests  24  21  20  
Total equity  37,221  37,058  35,154  
 
Table 23: Condensed consolidated statement of changes in equity 
 
 
 
Share 
capital  
Share 
premium 
account  
Other 
reserves  
Retained 
earnings  
Total 
attributable 
to owners of 
the parent  
Non-
controlling 
interests  
Total 
equity  
   $m  $m  $m  $m  $m  $m  $m  
At 1 Jan 2022  387  35,126  2,045  1,710  39,268  19  39,287  
Profit for the period  -  -  -  2,387  2,387  4  2,391  
Other comprehensive loss  -  -  -  (1,686) (1,686) (3) (1,689) 
Transfer to other reserves  -  -  36  (36) -  -  -  
Transactions with owners:         
Dividends  -  -  -  (4,486) (4,486) -  (4,486) 
Issue of Ordinary Shares  -  11  -  -  11  -  11  
Share-based payments charge 
for the period 
 -  -  -  471  471  -  471  
Settlement of share plan awards  -  -  -  (831) (831) -  (831) 
Net movement  -  11  36  (4,181) (4,134) 1  (4,133) 
At 30 Sep 2022  387  35,137  2,081  (2,471) 35,134  20  35,154  
         
At 1 Jan 2023  387  35,155  2,069  (574)  37,037  21  37,058  
Profit for the period  -  -  -  4,995  4,995  7  5,002  
Other comprehensive loss  -  -  -  (88)  (88)  -  (88)  
Transfer to other reserves  -  -  9  (9) -  -  -  
Transactions with owners:         
Dividends  -  -  -  (4,487) (4,487) -  (4,487)

===== SIDA 35 =====

35 
Dividends paid to non-controlling 
interests 
 -  -  -  -  -  (4)  (4) 
Issue of Ordinary Shares  -  11  -  -  11  -  11  
Share-based payments charge 
for the period 
 -  -  -  429  429  -  429  
Settlement of share plan awards  -  -  -  (700) (700) -  (700) 
Net movement  -  11  9  140  160  3  163  
At 30 Sep 2023  387  35,166  2,078  (434) 37,197  24  37,221  
 
Table 24: Condensed consolidated statement of cash flows 
 
For the nine months  ended 30 September   2023  2022  
 $m  $m  
 
Cash flows from operating activities    
Profit before tax  6,002  1,723  
Finance income and expense  945  936  
Share of after tax losses of associates and joint ventures  12  4  
Depreciation, amortisation and impairment  4,060  4,000  
Decrease in working capital and short-term provisions  150  3,458  
Gains on disposal of intangible assets  (247) (88) 
Fair value movements on contingent consideration arising from business 
combinations 
 202  293  
Non-cash and other movements  (623) (973) 
Cash generated from operations  10,501  9,353  
Interest paid  (826) (608) 
Tax paid  (1,710) (1,335) 
Net cash inflow from operating activities  7,965  7,410  
 
Cash flows from investing activities    
Acquisition of subsidiaries, net of cash acquired   (189)  -  
Payments upon vesting of employee share awards attributable to business 
combinations  
 (84) (297) 
Payment of contingent consideration from business combinations  (610) (570) 
Purchase of property, plant and equipment  (836) (719) 
Disposal of property, plant and equipment  131  17  
Purchase of intangible assets  (1,996) (1,298) 
Disposal of intangible assets  288  442  
Movement in profit-participation liability  190  -  
Purchase of non-current asset investments  (109) (28)  
Disposal of non-current asset investments  32  42  
Movement in short-term investments, fixed deposits and other investing 
instruments 
 (12)  (321)  
Payments to associates and joint ventures  -  (5)  
Interest received  208  26  
Net cash outflow from investing activities  (2,987) (2,711) 
Net cash inflow before financing activities  4,978  4,699  
 
Cash flows from financing activities    
Proceeds from issue of share capital  12  11  
Issue of loans and borrowings   3,816  -  
Repayment of loans and borrowings  (4,655) (1,261) 
Dividends paid  (4,479) (4,364) 
Hedge contracts relating to dividend payments  (19)  (127) 
Repayment of obligations under leases  (194) (182) 
Movement in short-term borrowings  110  378  
Payment of Acerta Pharma share purchase liability  (867)  (920)  
Net cash outflow from financing activities  (6,276) (6,465) 
Net decrease in Cash and cash equivalents in the period  (1,298) (1,766) 
Cash and cash equivalents at the beginning of the period  5,983  6,038  
Exchange rate effects  (66) (86) 
Cash and cash equivalents at the end of the period  4,619  4,186

===== SIDA 36 =====

36 
Cash and cash equivalents consist of:      
Cash and cash equivalents  4,871  4,458  
Overdrafts  (252) (272) 
  4,619  4,186  
 
Notes to the Interim financial statements 
 
Note 1: Basis of preparation and accounting policies 
 
These unaudited condensed consolidated Interim financial statements for the nine months ended 30 September 
2023 have been prepared in accordance with Internat ional Accounting Standard 34, ‘Interim Financial 
Reporting' (IAS 34), as issued by the International  Accounting Standards Board (IASB), IAS 34 as adopt ed by 
the European Union, UK-adopted IAS 34 and the Disclosure Guidance and Transparency Rules sourcebook of 
the United Kingdom's Financial Conduct Authority an d with the requirements of the Companies Act 2006 a s 
applicable to companies reporting under those standards. 
 
The unaudited Interim financial statements for the nine months ended 30 September 2023 were approved b y 
the Board of Directors for publication on 9 November 2023. 
 
This results announcement does not constitute statutory accounts of the Group within the meaning of sections 
434(3) and 435(3) of the Companies Act 2006. The annual financial statements of the Group for the year ended 
31 December 2022 were prepared in accordance with UK-adopted International Accounting Standards and with 
the requirements of the Companies Act 2006. The ann ual financial statements also comply fully with IFR Ss as 
issued by the IASB and International Accounting Standards as adopted by the European Union. Except for  the 
estimation of the interim income tax charge, the In terim financial statements have been prepared apply ing the 
accounting policies that were applied in the prepar ation of the Group's published consolidated financi al 
statements for the year ended 31 December 2022. 
 
The comparative figures for the financial year ended 31 December 2022 are not the Group's statutory accounts 
for that financial year. Those accounts have been reported on by the Group's auditors and have been delivered 
to the registrar of companies; their report was (i)  unqualified, (ii) did not include a reference to a ny matters to 
which the auditors drew attention by way of emphasi s without qualifying their report, and (iii) did no t contain a 
statement under section 498(2) or (3) of the Companies Act 2006. 
 
Alliance and Collaboration Revenues 
 
Effective 1 January 2023, the Group has updated the presentation of Total Revenue on the face of the Statement 
of Comprehensive Income to include Alliance Revenue  as a separate element to Collaboration Revenue. 
Alliance Revenue, previously reported within Collab oration Revenue, comprises income related to sales made 
by collaboration partners, where AstraZeneca is entitled to a profit share, revenue share or royalties, which are 
recurring in nature while the collaboration arrange ment remains in place. Alliance Revenue does not in clude 
Product Sales where AstraZeneca is leading commerci alisation in a territory. Collaboration Revenue ari sing 
from collaborative arrangements where the Group retains a significant ongoing economic interest and receives 
upfront amounts and event-triggered milestones, whi ch arise from the licensing of intellectual propert y, will 
continue to be reported as Collaboration Revenue. I n collaboration arrangements either AstraZeneca or the 
collaborator acts as principal in sales to the end customer. Where AstraZeneca acts as principal, we r ecord 
100% of sales to the end customer within Product Sa les. The revised presentation reflects the increasi ng 
importance of income arising from profit share arra ngements where collaboration partners are responsib le for 
booking revenues in some or all territories.  
 
The comparative revenue reported in 9M 2023 relatin g to the nine months to 30 September 2022 has been 
retrospectively adjusted to reflect the new split of Total Revenue, resulting in Alliance Revenue of $504m being 
reported for the nine months to 30 September 2022, however the combined total of Alliance Revenue and 
Collaboration Revenue is equal to the previously re ported Collaboration Revenue total for the nine mon ths to 
30 September 2022.  
  
Going concern 
The Group has considerable financial resources avai lable. As at 30 September 2023, the Group has $11.8 bn 
in financial resources (Cash and cash equivalent ba lances of $4.9bn and undrawn committed bank facilit ies of

===== SIDA 37 =====

37 
$6.9bn available, of which $2.0bn of the facilities  are available until February 2025 and the other $4 .9bn are 
available until April 2026, with $5.6bn of borrowin gs due within one year). These facilities contain n o financial 
covenants and were undrawn at 30 September 2023. 
 
The Group's revenues are largely derived from sales of medicines covered by patents which provide a relatively 
high level of resilience and predictability to cash  inflows, although government price interventions i n response 
to budgetary constraints are expected to continue t o adversely affect revenues in some of our signific ant 
markets. The Group, however, anticipates new revenu e streams from both recently launched medicines and  
those in development, and the Group has a wide dive rsity of customers and suppliers across different 
geographic areas. 
 
Consequently, the Directors believe that, overall, the Group is well placed to manage its business ris ks 
successfully. Accordingly, they continue to adopt t he going concern basis in preparing the Interim fin ancial 
statements. 
 
Legal proceedings 
The information contained in Note 6 updates the dis closures concerning legal proceedings and contingen t 
liabilities in the Group's Annual Report and Form 20-F Information 2022 . 
 
IAS 12 ‘Income Taxes' 
On 25 May 2023, the IASB issued an amendment to IAS  12 ‘Income Taxes' to clarify how the effects of th e 
global minimum tax framework should be accounted fo r and disclosed effective 1 January 2023. This was 
endorsed by the UK Endorsement Board on 19 July 202 3 and has been adopted by the Company for 2023 
reporting. The Company is currently assessing the potential impact of these rules upon its financial statements. 
The Company has applied the exception to recognisin g and disclosing information about deferred tax ass ets 
and liabilities related to Pillar 2 income taxes. 
 
Note 2: Intangible assets 
 
In accordance with IAS 36 ‘Impairment of Assets', reviews for triggers of impairment or impairment reversals at 
an individual asset or cash generating unit level were conducted, and impairment tests carried out where triggers 
were identified. As a result, total impairment char ges of $376m have been recorded against intangible assets 
during the nine months ended 30 September 2023 (9M 2022: $44m net charge). Impairment charges in respect 
of medicines in development were $359m (9M 2022: $6 1m net charge) including the $244m impairment of th e 
ALXN1840 intangible asset, following decision to discontinue this development programme in Wilson's disease. 
Impairment charges in respect of launched medicines were $17m (9M 2022: $nil). 
 
As previously disclosed, on 16 January 2023 AstraZeneca completed the acquisition of Neogene Therapeutics 
Inc. (Neogene), a global clinical-stage biotechnolo gy company pioneering the discovery, development an d 
manufacturing of next-generation T-cell receptor th erapies (TCR-Ts). The purchase price allocation exe rcise 
has completed, with the fair value of total conside ration determined at $267m. Intangible assets of $1 00m and 
goodwill of $158m were recognised in the acquisition balance sheet, as well as a cash outflow of $189m net of 
cash acquired. Future contingent milestones-based and non-contingent consideration is payable to a maximum 
of $120m. Neogene's results have been consolidated into the Group's results from 16 January 2023. 
 
The acquisition of CinCor completed on 24 February 2023, recorded as an asset acquisition, with consideration 
and net assets acquired of $1,268m, which included intangible assets acquired of $780m, $424m of cash and 
cash equivalents, and $75m of marketable securities . The Condensed consolidated statement of cash flow s 
includes a $1,204m payment for the intangible asset s which is presented net of the $424m cash and cash  
equivalents acquired within Purchase of intangible assets, whilst the $75m increase in marketable securities is 
presented within Movement in short-term investments , fixed deposits and other investing instruments. 
Contingent consideration of up to $496m could be pa id on achievement of regulatory milestones, and wil l be 
recognised when the associated milestones are triggered. 
 
Note 3: Net debt 
 
The table below provides an analysis of Net Debt and a reconciliation of Net Cash Flow to the movement in Net 
Debt. The Group monitors Net Debt as part of its ca pital-management policy as described in Note 28 of the 
Annual Report and Form 20-F Information 2022 . Net Debt is a non-GAAP financial measure.

===== SIDA 38 =====

38 
Table 25: Net debt 
 
  At 1 Jan 
2023  
Cash 
flow  
Acquisitions  Non-cash  
& other  
Exchange 
movements  
At 30 Sep 
2023  
  $m  $m  $m  $m  $m  $m  
Non-current instalments of loans  (22,965) (3,826) -  4,592  (26) (22,225)  
Non-current instalments of leases  (725) (1)  (6) (23)  11  (744) 
Total long-term debt  (23,690) (3,827) (6) 4,569  (15) (22,969)  
Current instalments of loans  (4,964) 4,655  -  (4,587) 39  (4,857) 
Current instalments of leases  (228)  215  (2)  (230) 10  (235) 
Bank collateral received  (89) (95) -  -  -  (184) 
Other short-term borrowings excluding 
overdrafts 
  
(78) (15) -  -  14  (79) 
Overdrafts  (183) (69) -  -  -  (252) 
Total current debt  (5,542) 4,691  (2) (4,817) 63  (5,607) 
Gross borrowings  (29,232) 864  (8) (248) 48  (28,576)  
Net derivative financial instruments  (96)  19  -  167  -  90  
Net borrowings  (29,328) 883  (8) (81)  48  (28,486)  
Cash and cash equivalents  6,166  (1,229) -  -  (66) 4,871  
Other investments - current  239  12  -  -  (7) 244  
Cash and investments  6,405  (1,217) -  -  (73) 5,115  
Net debt  (22,923) (334) (8)  (81)  (25) (23,371) 
 
Non-cash movements in the period include fair value adjustments under IFRS 9 Financial Instruments. 
 
The Group has agreements with some bank counterpart ies whereby the parties agree to post cash collater al 
on financial derivatives, for the benefit of the other, equivalent to the market valuation of the derivative positions 
above a predetermined threshold. The carrying value of such cash collateral held by the Group at 30 September 
2023 was $184m (31 December 2022: $89m) and the carrying value of such cash collateral posted by the Group 
at 30 September 2023 was $175m (31 December 2022: $162m). 
 
The equivalent GAAP measure to Net debt is ‘liabili ties arising from financing activities', which excl udes the 
amounts for cash and overdrafts, other investments and non-financing derivatives shown above and inclu des 
the Acerta Pharma share purchase liability of $819m (31 December 2022: $1,646m), which is shown in current 
other payables.  
 
Net debt increased by $448m in the nine months to 30 September 2023 to $23,371m. Details of the committed 
undrawn bank facilities are disclosed within the going concern section of Note 1.  
 
During the quarter to 30 September 2023, Moody's up graded the Company's solicited long term credit rat ing 
from A3 to A2 and its short term rating from P-2 to  P-1. Standard and Poor's credit ratings were uncha nged 
(long term: A; short term: A-1). 
 
Note 4: Financial Instruments 
 
As detailed in the Group's most recent annual finan cial statements, the principal financial instrument s consist 
of derivative financial instruments, other investme nts, trade and other receivables, cash and cash equ ivalents, 
trade and other payables, lease liabilities and interest-bearing loans and borrowings. 
 
The Group has certain equity investments that are c ategorised as Level 3 in the fair value hierarchy t hat are 
held at $281m at 30 September 2023 (31 December 2022: $186m) and for which fair value gains of $17m have 
been recognised in the nine months ended 30 Septemb er 2023 (9M 2022: $50m). In the absence of specific  
market data, these unlisted investments are held at fair value based on the cost of investment and adjusting as 
necessary for impairments and revaluations on new f unding rounds, which are seen to approximate the fa ir 
value. All other fair value gains and/or losses tha t are presented in Net gains/(losses) on equity inv estments 
measured at fair value through other comprehensive income in the Condensed consolidated statement of 
comprehensive income for the nine months ended 30 S eptember 2023 are Level 1 fair value measurements, 
valued based on quoted prices in active markets. 
  
Financial instruments measured at fair value includ e $1,296m of other investments, $3,551m held in mon ey-
market funds, $289m of loans designated at fair val ue through profit or loss and $90m of derivatives a s at 30 
September 2023. With the exception of derivatives b eing Level 2 fair valued, certain equity investment s as

===== SIDA 39 =====

39 
described above and an equity warrant of $14m categorised as Level 3, the aforementioned balances are Level 
1 fair valued. Financial instruments measured at am ortised cost include $175m of cash collateral pledg ed to 
counterparties. The total fair value of interest-bearing loans and borrowings at 30 September 2023, which have 
a carrying value of $28,576m in the Condensed consolidated statement of financial position, was $26,576m. 
 
As announced in April 2023, the contractual relationship between AstraZeneca and Swedish Orphan Biovitrum 
AB (Sobi) relating to future sales of Beyfortus  (nirsevimab) in the US has been replaced by a royalty relationship 
between Sanofi and Sobi. As a result, a non-current other payable representing AstraZeneca's future obligations 
to Sobi was eliminated from AstraZeneca's Statement of Financial Position in the quarter to 30 June 2023, and 
AstraZeneca recorded a gain of $712m in Core Other operating income.  
 
Table 26: Financial instruments - contingent consideration 
 
  2023 2022  
 
  Diabetes 
alliance  Other  Total  Total  
  $m  $m  $m  $m  
At 1 January  2,124  98  2,222  2,865  
Add itions through business combinations  -  60  60  -  
Settlements  (608)  (2) (610) (570) 
Disposals  -  -  -  (121)  
Revaluations  229  (27)  202  293  
Discount unwind  93  6  99  126  
At 30 September  1,838  135  1,973  2,593  
 
Contingent consideration arising from business comb inations is fair valued using decision-tree analysi s, with 
key inputs including the probability of success, co nsideration of potential delays and the expected le vels of 
future revenues. 
 
The contingent consideration balance relating to BM S's share of the global diabetes alliance of $1,838 m 
(31 December 2022: $2,124m) would increase/decrease by $184m with an increase/decrease in sales of 10%, 
as compared with the current estimates. 
 
Note 5: Pensions and other post-retirement benefit obligations 
 
During the nine months ended 30 September 2023, Ast raZeneca Pharmaceuticals PLP terminated its main 
defined benefit pension plan. A total of $839m of p ension obligations were discharged, $142m of which was 
settled via a cash payment to the participants and the remaining $697m was transferred to an external insurer 
via a buy-out. At 30 September 2023, the plan conta ined immaterial residual assets and obligations whi ch are 
expected to be discharged by the end of 2023, with minimal impact to the income statement. 
 
Note 6: Legal proceedings and contingent liabilities  
 
AstraZeneca is involved in various legal proceeding s considered typical to its business, including lit igation and 
investigations, including Government investigations , relating to product liability, commercial dispute s, 
infringement of intellectual property (IP) rights, the validity of certain patents, anti-trust law and  sales and 
marketing practices. The matters discussed below co nstitute the more significant developments since 
publication of the disclosures concerning legal pro ceedings in the Company's Annual Report and Form 20 -F 
Information 2022 and the Interim Financial Statements for the six months ended 30 June 2023 (the Disclosures). 
 
As discussed in the Disclosures, the majority of cl aims involve highly complex issues. Often these iss ues are 
subject to substantial uncertainties and, therefore , the probability of a loss, if any, being sustaine d and/or an 
estimate of the amount of any loss is difficult to ascertain. 
 
Unless specifically identified below, AstraZeneca considers each of the claims to represent a contingent liability 
or a contingent asset where the matter is brought by AstraZeneca, and discloses information with respect to the 
nature and facts of the cases in accordance with IAS 37. 
 
In cases that have been settled or adjudicated, or where quantifiable fines and penalties have been as sessed 
and which are not subject to appeal, or where a loss is probable and we are able to make a reasonable estimate 
of the loss, AstraZeneca records the loss absorbed or makes a provision for its best estimate of the e xpected 
loss. The position could change over time and the e stimates that the Company made, and upon which the

===== SIDA 40 =====

40 
Company have relied in calculating these provisions  are inherently imprecise. There can, therefore, be  no 
assurance that any losses that result from the outc ome of any legal proceedings will not exceed the am ount of 
the provisions that have been booked in the accounts. The major factors causing this uncertainty are described 
more fully in the Disclosures and herein. 
 
AstraZeneca has full confidence in, and will vigorously defend and enforce, its IP. 
 
Matters disclosed in respect of the third quarter of 2023 and to 9 November 2023 
 
Patent litigation 
 
Legal proceedings brought against AZ considered to be contingent liabilities 
 
Enhertu  
US patent proceedings 
In October 2020, Seagen Inc. (Seagen) filed a compl aint against Daiichi Sankyo Company, Limited (Daiic hi 
Sankyo) in the US District Court for the Eastern Di strict of Texas (District Court) alleging that Enhertu  infringes 
a Seagen patent. AstraZeneca Pharmaceuticals LP co-commercialises Enhertu  with Daiichi Sankyo, Inc. in the 
US. After trial in April 2022, the jury found that the patent was infringed and awarded Seagen $41.82m  in past 
damages. In July 2022, the District Court entered final judgment and declined to enhance damages on the basis 
of willfulness. In October 2023, the District Court  entered an amended final judgment that requires Da iichi 
Sankyo to pay Seagen a royalty of 8% on US sales of  Enhertu  from April 1, 2022 through November 4, 2024, 
in addition to the past damages previously awarded by the Court.  
 
In December 2020 and January 2021, AstraZeneca and Daiichi Sankyo, Inc. filed post-grant review (PGR) 
petitions with the US Patent and Trademark Office (USPTO) alleging, inter alia , that the Seagen patent is invalid 
for lack of written description and enablement. The  USPTO initially declined to institute the PGRs, bu t, in April 
2022, the USPTO granted the rehearing requests, ins tituting both PGR petitions. Seagen subsequently 
disclaimed all patent claims at issue in one of the  PGR proceedings. In July 2022, the USPTO reversed its 
institution decision and declined to institute the other PGR petition. AstraZeneca and Daiichi Sankyo requested 
reconsideration of the decision not to institute re view of the patent. In February 2023, the USPTO rei nstituted 
the PGR proceeding. An oral hearing took place in August 2023. The parties await a decision. 
 
Legal proceedings brought by AZ considered to be contingent assets 
 
Faslodex  
Patent proceedings outside the US  
In 2021 in Japan, AstraZeneca received notice from the Japan Patent Office (JPO) that Sandoz K.K. (San doz) 
and Sun Pharma Japan Ltd. (Sun) were seeking to inv alidate the Faslodex  formulation patent. AstraZeneca 
defended the challenged patent, and Sun withdrew from the JPO patent challenge. In July 2023, the JPO issued 
a final decision upholding various claims of the challenged patent and determining that other patent claims were 
invalid. In August 2023, Sandoz appealed the JPO decision to the Japan IP High Court. 
 
Calquence  
US patent proceedings  
In February 2022, in response to Paragraph IV notic es from multiple ANDA filers, AstraZeneca filed pat ent 
infringement lawsuits in the US District Court for the District of Delaware. In its complaint, AstraZeneca alleges 
that a generic version of Calquence , if approved and marketed, would infringe patents listed in the US FDA 
Orange Book with reference to Calquence  that are owned or licensed by AstraZeneca. Trial has been scheduled 
for March 2025. 
 
In February 2023, Sandoz Inc. filed a petition for inter partes review with the US Patent and Trademar k Office 
(USPTO) of certain Calquence  patent claims. AstraZeneca has asserted claims for patent infringement against 
Sandoz and other defendants in the US ANDA litigati on. In August 2023, the Patent Trial and Appeal Boa rd 
issued a decision denying institution of inter partes review.   
   
Product liability litigation   
 
Legal proceedings brought against AZ for which a provision has been taken 
 
Nexium  and Losec /Prilosec  
US proceedings

===== SIDA 41 =====

41 
In the US, AstraZeneca is defending various lawsuit s brought in federal and state courts involving mul tiple 
plaintiffs claiming that they have been diagnosed w ith various injuries following treatment with proto n pump 
inhibitors (PPIs), including Nexium  and Prilosec . The vast majority of those lawsuits related to al legations of 
kidney injuries. In August 2017, the pending federa l court cases were consolidated in a multidistrict litigation 
(MDL) proceeding in the US District Court for the District of New Jersey for pre-trial purposes. A bellwether trial 
had been scheduled for October 2023, with subsequen t bellwether trials scheduled for November 2023 and  
January 2024. In addition to the MDL cases, there were cases filed in Delaware and New Jersey state courts. 
 
In addition, AstraZeneca has been defending lawsuits involving allegations of gastric cancer following treatment 
with PPIs. One such claim was filed in the US District Court for the Middle District of Louisiana and is scheduled 
to go to trial in April 2024. 
 
In October 2023, AstraZeneca resolved all pending c laims in the MDL, as well as all of the pending cla ims in 
Delaware and New Jersey state courts, for $425m, for which a current provision has been taken. A single case 
remains pending in the US District Court for the Middle District of Louisiana.  
 
Legal proceedings brought against AZ considered to be contingent liabilities 
 
Farxiga  and Xigduo  XR 
US proceedings  
In several jurisdictions in the US, AstraZeneca has  been named as a defendant in lawsuits involving pl aintiffs 
claiming physical injury, including Fournier's Gang rene and necrotising fasciitis, from treatment with  Farxiga  
and/or Xigduo XR . A majority of these claims are filed in Delaware state court and remain pending. In September 
of 2023, the parties resolved by settlement one case, filed in state court in Minnesota, previously scheduled for 
trial in October 2023.  
 
Commercial litigation 
 
Legal proceedings brought against AZ for which a provision has been taken 
 
Alexion Shareholder Litigation (US)  
In December 2016, putative securities class action lawsuits were filed in the US District Court for the District of 
Connecticut (the District Court) against Alexion an d certain officers and directors, on behalf of purc hasers of 
Alexion publicly traded securities during the perio d 30 January 2014 through 26 May 2017. The amended 
complaint alleges that defendants engaged in securi ties fraud, including by making misrepresentations and 
omissions in its public disclosures concerning Alex ion's Soliris  sales practices, management changes, and 
related investigations. In August 2021, the Distric t Court issued a decision denying in part Defendant s' motion 
to dismiss the matter. The Court granted plaintiffs ' motion for class certification in April 2023. In August 2023, 
the parties reached a settlement in principle of th is matter. In September 2023, the court granted pre liminary 
approval of the class settlement. The court schedul ed a hearing in December 2023 to rule on final appr oval. A 
provision has been recognised in the quarter. 
 
Legal proceedings brought by AZ considered to be contingent assets 
 
US 340B litigations and proceedings  
US proceedings  
AstraZeneca has been involved in several matters relating to its contract pharmacy recognition policy under the 
340B Drug Pricing Program in the US.  
 
In August 2023, AstraZeneca filed a lawsuit against the Attorney General of the State of Louisiana alleging that 
the Louisiana's 340B statute, which requires manufa cturers to recognize an unlimited number of contrac t 
pharmacies, is preempted on several grounds and violates the Contracts Clause of the U.S. Constitution.  
 
In September 2023, the Arkansas Insurance Departmen t sent AstraZeneca an administrative complaint 
concerning compliance with Arkansas's 340B Statute,  which requires manufacturers to recognize an unlim ited 
number of contract pharmacies.  AstraZeneca response is due in November 2023.  
 
Inflation Reduction Act Litigation 
US proceedings  
In August 2023, AstraZeneca filed a lawsuit in the US District Court for the District of Delaware chal lenging 
aspects of the drug price negotiation provisions of  the Inflation Reduction Act and the implementing g uidance 
and regulations promulgated by the Department of Health and Human Services.

===== SIDA 42 =====

42 
 
Government investigations/proceedings 
 
Legal proceedings brought against AZ considered to be contingent liabilities 
 
340B Qui Tam 
US Proceedings  
In July 2023, AstraZeneca was served with an unseal ed civil lawsuit brought by a qui tam relator on be half of 
the United States, several states, and the District  of Columbia in the United States District Court fo r Central 
District of California. The complaint alleges that AstraZeneca violated the False Claims Act and State -Law 
Counterparts. In September 2023, AstraZeneca filed a motion to dismiss the relator's claims.  
 
Subsequent events  
 
In November, AstraZeneca announced a collaboration and investment agreement with Cellectis, a clinical-stage 
biotechnology company, to accelerate the developmen t of next generation therapeutics in areas of high unmet 
need, including oncology, immunology and rare disea ses. In Q4 2023, under the terms of the collaborati on 
agreement, Cellectis will receive an initial paymen t of $105m from AstraZeneca, which comprises a $25m  
upfront cash payment and an $80m equity investment.  AstraZeneca expects to treat its investment in Cel lectis 
as an associate. 
 
In November, AstraZeneca and Eccogene entered into an exclusive licence agreement for ECC5004, an 
investigational oral once-daily GLP-1RA for the treatment of obesity, type-2 diabetes and other cardiometabolic 
conditions. Under the terms of the agreement, Astra Zeneca obtained exclusive global rights for develop ment 
and commercialisation in all territories except Chi na where Eccogene has the right to co-develop and c o-
commercialise alongside AstraZeneca. Eccogene will receive an initial upfront payment of $185m and up to an 
additional $1.825bn in future clinical, regulatory, and commercial milestones and tiered royalties. 
 
Note 7 
Table 27: 9M 2023 - Product Sales year-on-year analysis 
86  
 
 World  US  Emerging Markets  Europe  
 
 
$m  Act % chg  CER % chg  $m  % chg  $m  Act % chg  CER % chg  $m  Act % chg  CER % chg 
Oncology  12,692   17   20   5,652   20   2,925   7  15   2,428   19   
Tagrisso  4,380  7  10  1,679  14  1,261  4  11  821  6  
Imfinzi  3,102  53  56  1,708  55  270  20  31  547  36  
Lynparza  2,070  6  9  902  1  409  14  24  543  10  
Calquence  1,839  25  26  1,337  12  69  n/m  n/m  353  76  
Enhertu  178  n/m  n/m  -  -  121  n/m  n/m  40  n/m  
Orpathys  33  (3) 4  -  -  33  (3) 4  -  -  
Zoladex  699  (3) 5  12  9  521  3  11  98  (2) 
Faslodex  217  (16) (10) 9  (38) 113  (6)  -  22  (50)  
Others 174  (36) (32) 5  (36) 128  (38) (34) 4  (41) 
BioPharmaceuticals: CVRM 7,887  14  18  1,972  11  3,507  10  18  1,825  29  
Farxiga  4,358  36  40  1,000  34  1,653  35  43  1,356  42  
Brilinta  996  (2) -  551  2  224  1  10  203  (5) 
Lokelma 300  44  49  156  28  37  n/m  n/m  41  98  
roxadustat  208  41  51  -  -  208  41  51  -  -  
Andexxa  129  16  19  57  (8) -  -  -  44  51  
Crestor 860  4  11  40  (19) 678  8  15  41  38  
Seloken /Toprol-XL 496  (30) (23) -  -  482  (30) (24) 8  (19) 
Onglyza  180  (12) (8) 44  (26) 99  1  9  25  (17) 
Bydureon  123  (40) (40) 101  (43) 2  15  14  20  (30) 
Others  237  (16) (13) 23  (13) 124  (19) (13) 87  (10) 
BioPharmaceuticals: R&I 4,517  5  8  1,900  (3) 1,315  19  29  847  7  
Symbicort  1,842  (4)  (1)  589  (18) 600  26  36  408  (8) 
Fasenra  1,134  12  13  718  11  48  62  69  262  14  
Breztri 478  69  73  263  60  123  73  86  55  n/m  
Saphnelo 191  n/m  n/m  178  n/m  1  n/m  n/m  5  n/m  
Tezspire 51  n/m  n/m  -  -  -  -  -  28  n/m  
Pulmicort  493  3  10  22  (58) 392  16  24  49  (1)  
Bevespi  42  (2) (2) 24  (23)  5  21  32  12  70  
Daliresp/Daxas  41  (74) (74) 32  (79) 2  (23) (10) 6  (9) 
Others  245  (30)  (27) 74  (44) 144  (20)  (14) 22  (35) 
BioPharmaceuticals: V&I 667  (82) (81) 15  (98)  181  (82) (81) 236  (66) 
COVID-19 mAbs  126  (91) (90) -  n/m  5  (97) (97) 7  (97) 
Vaxzevria  28  (98)  (98)  -  n/m  18  (97)  (97)  10  (97) 
Beyfortus 52  n/m  n/m  -  -  -  -  -  52  -  
Synagis  383  -  6  (1)  n/m  158  9  15  109  (12) 
 
86  The table provides an analysis of year-on-year Product Sales, with Actual and CER growth rates reflecting year-on-year growth. Due to 
rounding, the sum of a number of dollar values and percentages may not agree to totals.  
Financial Statements

===== SIDA 43 =====

43 
FluMist  78  32  28  16  44  -  n/m  n/m  58  28  
Rare Disease 5,793  11  12  3,469  9  487  54  68  1,165  8  
Soliris 2,429  (17) (15) 1,313  (22) 338  55  74  530  (15) 
Ultomiris 2,141  56  58  1,260  63  47  38  39  495  43  
Strensiq 847  23  24  690  26  29  14  16  64  9  
Koselugo  246  65  65  144  26  49  n/m  n/m  38  n/m  
Kanuma 130  17  18  62  11  24  53  55  38  13  
Other medicines 910  (27)  (22)  104  (7) 580  (5) 3  67  (29) 
Nexium 735  (25) (20) 88  (6)  458  5  14  36  (1) 
Others 175  (33) (31) 16  (13) 122  (29) (25) 31  (47) 
Total Product Sales  32,466  1  4  13,112  3  8,995  1  8  6,568  7  
 
Table 28: Q3 2023 - Product Sales year-on-year analysis 87  
 
 World  US  Emerging Markets  Europe  
 
 
$m  Act % chg  CER % chg  $m  % chg  $m  Act % chg  CER % chg  $m  Act % chg  CER % chg 
Oncology  4, 389   16   17   1, 986   16   971   4  13   849   22   
Tagrisso  1,465  5  6  577  11  409  1  8  281  5  
Imfinzi  1,126  53  54  610  48  87  (4)  7  208  54  
Lynparza  702  7  8  322  3  131  12  26  178  8  
Calquence  654  16  15  468  2  28  n/m  n/m  128  63  
Enhertu  73  n/m  n/m  -  -  48  n/m  n/m  16  n/m  
Orpathys  12  6  13  -  -  12  6  13  -  -  
Zoladex  239  -  5  5  29  182  4  11  31  (1)  
Faslodex  64  (21) (16) 3  (41)  32  (19)  (13)  6  (53) 
Others 54  (33) (30) 1  (59) 42  (34) (32) 1  11  
BioPharmaceuticals: CVRM 2,683  14  16  690  9  1,161  7  15  657  40  
Farxiga  1,554  41  41  366  31  579  41  48  506  54  
Brilinta  331  (2) (1) 193  4  64  (16)  (4)  68  4  
Lokelma 102  30  31  51  15  13  39  48  16  97  
roxadustat  74  31  39  -  -  74  30  39  -  -  
Andexxa  40  (3)  (5)  20  -  -  -  -  15  32  
Crestor 275  (1)  6  14  (10) 219  2  9  9  6  
Seloken /Toprol-XL 153  (36) (29) -  -  149  (36) (29) 2  (45) 
Onglyza  53  (20) (17) 9  (57)  33  -  9  8  (9) 
Bydureon  35  (48) (49) 28  (52) 1  97  90  6  (25)  
Others  66  (23) (21) 9  15  29  (40) (37) 27  (1) 
BioPharmaceuticals: R&I 1,451  2  3  609  (8)  422  14  23  266  9  
Symbicort  555  (12) (10)  156  (34) 195  15  24  123  (7) 
Fasenra  389  10  10  249  9  19  56  67  86  12  
Breztri 171  66  69  98  69  42  51  62  19  n/m  
Saphnelo 76  n/m  n/m  71  n/m  -  -  -  2  n/m  
Tezspire 21  n/m  n/m  -  -  -  -  -  11  n/m  
Pulmicort  148  2  7  5  (69) 119  16  24  13  (11) 
Bevespi  13  (5) (4) 8  (23) 2  (2)  7  3  77  
Daliresp/Daxas  11  (79) (79) 8  (83) -  (36) (2) 2  (2) 
Others  67  (31) (28) 14  (55) 45  (20) (14) 7  (14) 
BioPharmaceuticals: V&I 224  (74) (74) 15  (95)  32  (76) (75) 122  (33) 
COVID-19 mAbs  -  n/m  n/m  -  n/m  -  n/m  n/m  -  n/m  
Vaxzevria  -  n/m  n/m  -  -  -  n/m  n/m  -  n/m  
Beyfortus 50  n/m  n/m  -  -  -  -  -  50  -  
Synagis  99  (5)  (1)  -  -  32  (13)  (7)  16  (4) 
FluMist  75  28  23  15  41  -  -  -  56  22  
Rare Disease 1,974  13  14  1,179  9  163  49  70  397  15  
Soliris 781  (13) (12) 420  (20) 124  47  71  163  (14) 
Ultomiris 777  50  49  445  41  17  n/m  n/m  184  51  
Strensiq 285  20  21  237  23  5  (32) (10) 22  17  
Koselugo  87  81  81  54  51  11  51  69  15  n/m  
Kanuma 44  21  19  23  27  6  (4)  (2)  13  31  
Other medicines  297   (27 ) (22 ) 36   (3) 190   (11 ) (4) 19   (32 ) 
Nexium  244  (22) (17) 29  (6)  153  3  13  11  5  
Others 53  (43) (41) 7  10  37  (44) (41) 8  (54) 
Total Product Sales  11,018   4  5  4, 515   2  2, 939   3  12   2, 310   18   
 
Table 29: Alliance Revenue  
 
  9M 2023  9M 2022  
  $m  $m  
Enhertu   741  335  
Tezspire  179  42  
Vaxzevria: royalties   -  67  
Other royalty income  59  51  
Other Alliance Revenue  25  9  
 
87  The table provides an analysis of year-on-year Product Sales, with Actual and CER growth rates reflecting year-on-year growth. Due to 
rounding, the sum of a number of dollar values and percentages may not agree to totals.

===== SIDA 44 =====

44 
Total  1,004  504  
 
Table 30: Collaboration Revenue  
 
  9M 2023  9M 2022  
  $m  $m  
Lynparza : regulatory milestones  -  250  
COVID-19 mAbs: licence fees  180  -  
Farxiga : sales milestones   28  -  
tralokinumab: sales milestones   20  110  
Beyfortus : regulatory milestones   71  -  
Other Collaboration Revenue  18  80  
Total  317  440  
 
Table 31: Other operating income and expense 
 
  9M 2023  9M 2022  
  $m  $m  
brazikumab licence termination funding  75  104  
Divestment of rights to Plendil   -  61  
Divestment of US rights to Pulmicort  Flexhaler   241  -  
Update to the contractual relationships for Beyfortus  (nirsevimab)  712  -  
Other   205  160  
Total  1,233  325  
 
Other shareholder information 
 
Financial calendar 
 
Announcement of full year and fourth quarter 2023 results: 8 February 2024 
 
Dividends are normally paid as follows: 
First interim:  Announced with the half year result s and paid in September 
Second interim: Announced with full year results an d paid in March 
 
Contacts 
 
For details on how to contact the Investor Relations Team, please click here. For Media contacts, click here. 
 
 
Addresses for correspondence  
 
    
Registered office Registrar and 
transfer office 
Swedish Central 
Securities Depository 
US depositary 
Deutsche Bank Trust 
Company Americas 
1 Francis Crick Avenue 
Cambridge Biomedical 
Campus 
Cambridge 
CB2 0AA 
Equiniti Limited 
Aspect House 
Spencer Road 
Lancing 
West Sussex 
BN99 6DA 
Euroclear Sweden AB PO 
Box 191 
SE-101 23 Stockholm 
American Stock Transfer 
6201 15th Avenue 
Brooklyn 
NY 11219  
United Kingdom United Kingdom Sweden United States 
    
+44 (0) 20 3749 5000 0800 389 1580 +46 (0) 8 402 90 00 +1 (888) 697 8018 
 +44 (0) 121 415 7033  +1 (718) 921 8137 
   db@astfinancial.com

===== SIDA 45 =====

45 
Trademarks 
 
Trademarks of the AstraZeneca group of companies ap pear throughout this document in italics. Medical 
publications also appear throughout the document in  italics. AstraZeneca, the AstraZeneca logotype and  the 
AstraZeneca symbol are all trademarks of the AstraZ eneca group of companies. Trademarks of companies 
other than AstraZeneca that appear in this document include Arimidex and Casodex , owned by AstraZeneca or 
Juvisé (depending on geography); Beyfortus , a trademark of Sanofi Pasteur Inc.; Enhertu,  a trademark of 
Daiichi Sankyo; Losec, owned by AstraZeneca or Cheplapharm (depending upon geography); Seloken , owned 
by AstraZeneca or Taiyo Pharma Co., Ltd (depending on geography); Synagis , owned by AstraZeneca or Sobi 
aka Swedish Orphan Biovitrum AB (publ). (depending on geography); and Tezspire , a trademark of Amgen, Inc. 
 
Information on or accessible through AstraZeneca's websites, including astrazeneca.com, does not form part 
of and is not incorporated into this announcement. 
 
AstraZeneca 
 
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the 
discovery, development, and commercialisation of pr escription medicines in Oncology, Rare Disease, and  
BioPharmaceuticals, including Cardiovascular, Renal  & Metabolism, and Respiratory & Immunology. Based in 
Cambridge, UK, AstraZeneca operates in over 100 cou ntries and its innovative medicines are used by millions 
of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca. 
 
Cautionary statements regarding forward-looking statements 
 
In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform 
Act of 1995, AstraZeneca (hereafter ‘the Group') provides the following cautionary statement: 
 
This document contains certain forward-looking stat ements with respect to the operations, performance and 
financial condition of the Group, including, among other things, statements about expected revenues, margins, 
earnings per share or other financial or other measures. Although the Group believes its expectations are based 
on reasonable assumptions, any forward-looking stat ements, by their very nature, involve risks and 
uncertainties and may be influenced by factors that  could cause actual outcomes and results to be mate rially 
different from those predicted. The forward-looking  statements reflect knowledge and information avail able at 
the date of preparation of this document and the Group undertakes no obligation to update these forward-looking 
statements. The Group identifies the forward-lookin g statements by using the words 'anticipates', 'bel ieves', 
'expects', 'intends' and similar expressions in such statements. Important factors that could cause actual results 
to differ materially from those contained in forward-looking statements, certain of which are beyond the Group's 
control, include, among other things: 
 
‒ the risk of failure or delay in delivery of pipeli ne or launch of new medicines 
‒ the risk of failure to meet regulatory or ethical requirements for medicine development or approval 
‒ the risk of failures or delays in the quality or e xecution of the Group's commercial strategies 
‒ the risk of pricing, affordability, access and com petitive pressures 
‒ the risk of failure to maintain supply of complian t, quality medicines 
‒ the risk of illegal trade in the Group's medicines  
‒ the impact of reliance on third-party goods and se rvices 
‒ the risk of failure in information technology or c ybersecurity 
‒ the risk of failure of critical processes 
‒ the risk of failure to collect and manage data in line with legal and regulatory requirements and str ategic 
objectives 
‒ the risk of failure to attract, develop, engage an d retain a diverse, talented and capable workforce 
‒ the risk of failure to meet regulatory or ethical expectations on environmental impact, including cli mate 
change 
‒ the risk of the safety and efficacy of marketed me dicines being questioned 
‒ the risk of adverse outcome of litigation and/or g overnmental investigations 
‒ intellectual property-related risks to our product s 
‒ the risk of failure to achieve strategic plans or meet targets or expectations 
‒ the impact that global and/or geopolitical events may have or continue to have on these risks, on the Group's 
ability to continue to mitigate these risks, and on  the Group's operations, financial results or finan cial 
condition

===== SIDA 46 =====

46 
‒ the risk of failure in financial control or the oc currence of fraud 
‒ the risk of unexpected deterioration in the Group' s financial position 
 
Nothing in this document, or any related presentation/webcast, should be construed as a profit forecast. 
 
- End of document -